header logo image


Page 32«..1020..31323334..4050..»

Archive for May, 2020

Precision Medicine Market 2019: Industry Analysis and Detailed Profiles of Top Industry Players are Neon Therapeutics, Moderna, Inc, Merck & Co.,…

Sunday, May 17th, 2020

Global Precision Medicine market report provides an in-depth overview of Product Specification, technology, product type and production analysis considering major factors such as Revenue, Cost, Gross and Gross Margin. The company profiles of all the key players and brands that are dominating the Precision Medicine market with moves like product launches, joint ventures, merges and accusations which in turn is affecting the sales, import, export, revenue and CAGR values are mentioned in the report. The report is generated based on the market type, size of the organization, availability on-premises and the end-users organization type, and the availability in areas such as North America, South America, Europe, Asia-Pacific and Middle East & Africa.

Global Precision Medicine Marketto grow with a substantial CAGR in the forecast period of 2019-2026. Growing prevalence of cancer worldwide and accelerating demand of novel therapies to prevent of cancer related disorders are the key factors for lucrative growth of market

Key Market Players:

Few of the major competitors currently working in the global precision medicine market are Neon Therapeutics, Moderna, Inc, Merck & Co., Inc, Bayer AG, PERSONALIS INC, GENOCEA BIOSCIENCES, INC., F. Hoffmann-La Roche Ltd, CureVac AG, CELLDEX THERAPEUTICS, BIONTECH SE, Advaxis, Inc, GlaxoSmithKline plc, Bioven International Sdn Bhd, Agenus Inc., Immatics Biotechnologies GmbH, Immunovative Therapies, Bristol-Myers Squibb Company, Gritstone Oncology, NantKwest, Inc among others.

Download Free PDF Sample Copy ofReport@http://databridgemarketresearch.com/request-a-sample/?dbmr=global-precision-medicine-market

Global Precision Medicine MarketBy Application (Diagnostics, Therapeutics and Others), Technologies (Pharmacogenomics, Point-of-Care Testing, Stem Cell Therapy, Pharmacoproteomics and Others), Indication (Oncology, Central Nervous System (CNS) Disorders, Immunology Disorders, Respiratory Disorders, Others), Drugs (Alectinib, Osimertinib, Mepolizumab,Aripiprazole lauroxil and Others), Route of Administration (Oral,Injectable), End- Users (Hospitals, Homecare, Specialty Clinics, Others), Geography (North America, South America, Europe, Asia-Pacific, Middle East and Africa) Industry Trends and Forecast to 2026

Competitive Analysis:

The precision medicine market is highly fragmented and is based on new product launches and clinical results of products. Hence the major players have used various strategies such as new product launches, clinical trials, market initiatives, high expense on research and development, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of mass spectrometry market for global, Europe, North America, Asia Pacific and South America.

Market Drivers

Market Restraints

Talk to The Author of Report @http://databridgemarketresearch.com/speak-to-analyst/?dbmr=global-precision-medicine-market

Market Definition:

Precision medicines is also known as personalized medicines is an innovative approach to the patient care for disease treatment, diagnosis and prevention base on the persons individual genes. It allows doctors or physicians to select treatment option based on the patients genetic understanding of their disease.

According to the data published in PerMedCoalition, it was estimated that the USFDA has approved 25 novels personalized medicines in the year of 2018. These growing approvals annually by the regulatory authorities and rise in oncology and CNS disorders worldwide are the key factors for market growth.

Grab Your Report at an Impressive 30% Discount! Please clickHere@https://www.databridgemarketresearch.com/request-a-discount/global-precision-medicine-market

Key Developments in the Market:

Competitive Analysis:

Global precision medicine market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of global precision medicine market for Global, Europe, North America, Asia-Pacific, South America and Middle East & Africa.

Market Segmentation:

By technology:-big data analytics, bioinformatics, gene sequencing, drug discovery, companion diagnostics, and others.

By application:- oncology, hematology, infectious diseases, cardiology, neurology, endocrinology, pulmonary diseases, ophthalmology, metabolic diseases, pharmagenomics, and others.

On the basis of end-users:- pharmaceuticals, biotechnology, diagnostic companies, laboratories, and healthcare it specialist.

On the basis of geography:- North America & South America, Europe, Asia-Pacific, and Middle East & Africa. U.S., Canada, Germany, France, U.K., Netherlands, Switzerland, Turkey, Russia, China, India, South Korea, Japan, Australia, Singapore, Saudi Arabia, South Africa, and Brazil among others.

In 2017, North America is expected to dominate the market.

About Data Bridge Market Research:

Data Bridge Market Researchset forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Contact:

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Email:Corporatesales@databridgemarketresearch.com

Excerpt from:
Precision Medicine Market 2019: Industry Analysis and Detailed Profiles of Top Industry Players are Neon Therapeutics, Moderna, Inc, Merck & Co.,...

Read More...

Coronavirus (COVID-19) Impact on Mucopolysaccharidosis Treatment Market Status, Players, Types, Applications, and Forecast 2020-2029 3w Market News…

Sunday, May 17th, 2020

Recent Trends In Mucopolysaccharidosis Treatment Market 2020: Scenario Highlighting Major Drivers, Explores New Growth Opportunities, Developments and Future Forecasts To 2029

The innovative research report provides details on current and future growth trends as well as information on regions across the geographical landscape of the Mucopolysaccharidosis Treatment market. Future scope analysis of Mucopolysaccharidosis Treatment Market with systematic evaluation of the competitors offers a clear idea of the most fundamental challenges in the current market and the coming years. This top research report highlights the leading growth drivers, restraints, challenges, trends, and opportunities. This Report covers the Major players data, including- competitive situation, sales, revenue, and global market share of top manufacturers. Leading Companies are ArmaGen Inc., Others, BioMarin Pharmaceutical Inc., a Sanofi Company, Genzyme, Sangamo Therapeutics and Hamilton Storage Technologies.

Get Research Insights at (Use official eMail ID to Get Higher Priority): https://market.us/report/mucopolysaccharidosis-treatment-market/request-sample/

[Note: Our Free Complimentary Sample Report Accommodate a Brief Introduction To The Synopsis, TOC, List of Tables and Figures, Competitive Landscape and Geographic Segmentation, Innovation and Future Developments Based on Research Methodology are also Included]

The report aims to Outline and forecast, Top Vendors, industry research and end-user analysis and also provide to the reader a professional and in-depth industry analysis no matter you are the industry insider potential entrant or investor. A brief study of the industry with regards to market size concerning remuneration and volume aspects along with the current Mucopolysaccharidosis Treatment market shares scenario is offered in the research report. The report is all around made by considering its necessary information in the comprehensive global Mucopolysaccharidosis Treatment market.

In a detailed analysis of growth opportunities, investment feasibility, challenges, and obstacles to market development are covered in this report.Detailed research on market size, the share of leading industry players.Forecast information related to the Mucopolysaccharidosis Treatment market size and growth, consumer base and emerging market segments are elaborated in-depth in this Mucopolysaccharidosis Treatment report.Region-wise Mucopolysaccharidosis Treatment analysis will cover all the key factors related to revenue and Mucopolysaccharidosis Treatment market share of the leading industry players.An in-depth study of business profiles of the top Mucopolysaccharidosis Treatment players along with their revenue, consumer volume will help in planning business strategies.Marketing strategies, emerging trends in the industry, and comprehensive analysis of Mucopolysaccharidosis Treatment will lead to market development.Analysis of the major competitors in the market: BioMarin Pharmaceutical Inc.Genzymea Sanofi CompanyArmaGen Inc.Sangamo TherapeuticsOthersHamilton Storage TechnologiesProduct Type Coverage:Enzyme Replacement TherapyStem Cell TherapyOthersApplication Coverage: HospitalsClinicsSpecialty Care UnitOthersFollowing regions and Sub-regions are covered in this reportSouth America Mucopolysaccharidosis Treatment Market Covers Colombia, Brazil and ArgentinaNorth America Mucopolysaccharidosis Treatment Market Covers Canada, Mexico and United StatesEurope Mucopolysaccharidosis Treatment Market Covers Russia, Germany, Italy, UK and FranceThe Middle East and Africa Mucopolysaccharidosis Treatment Market Covers South Africa, UAE, Saudi Arabia, Nigeria and EgyptAsia Pacific Mucopolysaccharidosis Treatment Market Covers China, India, Southeast Asia, Japan and KoreaRead more details of the report at: https://market.us/report/mucopolysaccharidosis-treatment-market/#inquiry

[Note: Use Corporate eMail ID and Business Details to Get Higher Priority]

In-Depth Insight Of Mucopolysaccharidosis Treatment Market :Future Growth Of Mucopolysaccharidosis Treatment market By New Business Developments, Innovations, And Top Companies Forecast To 2029Determine Key Opportunities in the market sales scenario by analyzing trends in authorizing and co-development deals.The trend of Mucopolysaccharidosis Treatment market in the global industry with Market Development, Analysis, and Overview 2020-2029.Study the market in terms of generic and premium product revenue.Assessment of the global industry trends, historical data from 2012 to 2017, projections for the coming years, and anticipation of compound annual growth rates (CAGRs) by the end of the forecast period.Wide-ranging company profiles of leading participants in the industry.The composition of the market, in terms of dynamic molecule types and targets, underlining the major industry resources and players.Discoveries of new market prospects and targeted marketing methodologies for Global Mucopolysaccharidosis Treatment Market.Click Here to Buy Mucopolysaccharidosis Treatment Market Report: https://market.us/request-covid-19/?report_id=30107

Mucopolysaccharidosis Treatment Market IntroductionDefinitionTaxonomyResearch Scope

Executive SummaryKey Findings by Major SegmentsTop strategies by Major Players

Global Mucopolysaccharidosis Treatment Market OverviewMucopolysaccharidosis Treatment Market DynamicsDriversOpportunitiesRestraintsChallenges

PESTLE AnalysisOpportunity Map AnalysisPORTERS Five Forces AnalysisMarket Competition Scenario AnalysisProduct Life Cycle AnalysisOpportunity OrbitsManufacturer Intensity Map

Global Mucopolysaccharidosis Treatment Market Value (US$ Mn), Share (%), and Growth Rate (%) Comparison by TypeGlobal Mucopolysaccharidosis Treatment Market Analysis by Type: IntroductionGlobal Mucopolysaccharidosis Treatment Market Size and Forecast by Region

Global Mucopolysaccharidosis Treatment Market Value (US$ Mn), Share (%), and Growth Rate (%) Comparison by ApplicationGlobal Mucopolysaccharidosis Treatment Market Analysis by Application: IntroductionGlobal Mucopolysaccharidosis Treatment Market Size and Forecast by Region

Global Mucopolysaccharidosis Treatment Market Value (US$ Mn), Share (%), and Growth Rate (%) Comparison by RegionGlobal Mucopolysaccharidosis Treatment Market Competitive Landscape, Market Share Analysis, and Company ProfilesMarket Share AnalysisCompany ProfilesCompany OverviewFinancial HighlightsProduct PortfolioSWOT AnalysisKey Strategies and DevelopmentsAssumptions and AcronymsResearch MethodologyContact

View Mucopolysaccharidosis Treatment Market Report TOC In detail: https://market.us/report/mucopolysaccharidosis-treatment-market/#toc

Contact Us:

Mr. Benni JohnsonMarket.us (Powered By Prudour Pvt. Ltd.)Tel: +1 718 618 4351.Email: [emailprotected]

Refer our Trending Reports:

Drilling Fluid Additives Market | 2020 Report with Manufacturers, Dealers, Consumers, Revenue, Regions, Types, Application 2029https://apnews.com/Wired%20Release/0630abc460566dcebbb6a008b62c957f

Trending News For Marine Power Market Rising Business Opportunities With Prominent Investment Ratio By 2029https://www.marketwatch.com/press-release/trending-news-for-marine-power-market-rising-business-opportunities-with-prominent-investment-ratio-by-2029-2020-02-05

Frameless TV Market Size, Shares, Growth Analysis, and Forecast 2020-2029Global Frameless TV Market By Type( >40 Inch, 40~50 Inch, 50~60 Inch, 60~70 Inch, >70 Inch ); By Application( Commercial, Residential ); By Region and Key Companies( LG, Panasonic, Samsung, Sceptre, Seiki, Sharp, Sony, TCL, Upstar, Vizio, Hisense, Hair, Philips, Toshiba ):-Industry Segment Outlook Analysis, Market Assessment, Competition Scenario Analysis, Global Trends and Forecast 2020-2029https://techmarketreports.com/report/frameless-tv-market/

Continue reading here:
Coronavirus (COVID-19) Impact on Mucopolysaccharidosis Treatment Market Status, Players, Types, Applications, and Forecast 2020-2029 3w Market News...

Read More...

CRISPR And CRISPR-Associated (Cas) Genes Market which company is the market leader and how much its sales in 2020 and what it’s expected sales for the…

Sunday, May 17th, 2020

Los Angeles, United StatesThe report offers an all-inclusive and accurate research study on the global CRISPR And CRISPR-Associated (Cas) Genes market while chiefly focusing on current and historical market scenarios. Stakeholders, market players, investors, and other market participants can significantly benefit from the thorough market analysis provided in the report. The authors of the report have compiled a detailed study on crucial market dynamics, including growth drivers, restraints, and opportunities. This study will help market participants to get a good understanding of future development of the global CRISPR And CRISPR-Associated (Cas) Genes market. The report also focuses on market taxonomy, regional analysis, opportunity assessment, and vendor analysis to help with comprehensive evaluation of the global CRISPR And CRISPR-Associated (Cas) Genes market.

Key companies operating in the global CRISPR And CRISPR-Associated (Cas) Genes market include : , Caribou Biosciences, Addgene, CRISPR THERAPEUTICS, Merck KGaA, Mirus Bio LLC, Editas Medicine, Takara Bio USA, Thermo Fisher Scientific, Horizon Discovery Group, Intellia Therapeutics, GE Healthcare Dharmacon CRISPR And CRISPR-Associated (Cas) Genes

Get PDF Sample Copy of the Report to understand the structure of the complete report: (Including Full TOC, List of Tables & Figures, Chart) :

https://www.qyresearch.com/sample-form/form/1704011/covid-19-impact-on-global-crispr-and-crispr-associated-cas-genes-market

Segment Analysis

The segmental analysis will help companies to focus on high-growth areas of the global CRISPR And CRISPR-Associated (Cas) Genes market. In order to broaden the overall understanding of the global CRISPR And CRISPR-Associated (Cas) Genes industry, the report has segregated the global CRISPR And CRISPR-Associated (Cas) Genes business into varied segments comprising product type, application, and end user. This examination has been carried out based on parameters like size, CAGR, share, production, and consumption. Also, region-wise assessment, wherein lucrative prospects that a region or country is likely to offer has been explored.

Global CRISPR And CRISPR-Associated (Cas) Genes Market Segment By Type:

, Genome Editing, Genetic engineering, gRNA Database/Gene Librar, CRISPR Plasmid, Human Stem Cells, Genetically Modified Organisms/Crops, Cell Line Engineering CRISPR And CRISPR-Associated (Cas) Genes

Global CRISPR And CRISPR-Associated (Cas) Genes Market Segment By Application:

, Genome Editing, Genetic engineering, gRNA Database/Gene Librar, CRISPR Plasmid, Human Stem Cells, Genetically Modified Organisms/Crops, Cell Line Engineering CRISPR And CRISPR-Associated (Cas) Genes

Competitive Landscape:

It is important for every market participant to be familiar with the competitive scenario in the global CRISPR And CRISPR-Associated (Cas) Genes industry. In order to fulfill the requirements, the industry analysts have evaluated the strategic activities of the competitors to help the key players strengthen their foothold in the market and increase their competitiveness.

Key companies operating in the global CRISPR And CRISPR-Associated (Cas) Genes market include : , Caribou Biosciences, Addgene, CRISPR THERAPEUTICS, Merck KGaA, Mirus Bio LLC, Editas Medicine, Takara Bio USA, Thermo Fisher Scientific, Horizon Discovery Group, Intellia Therapeutics, GE Healthcare Dharmacon CRISPR And CRISPR-Associated (Cas) Genes

Key Questions Answered

Enquire for Customization in this Report: https://www.qyresearch.com/customize-request/form/1704011/covid-19-impact-on-global-crispr-and-crispr-associated-cas-genes-market

Table of Contents

1 Study Coverage1.1 CRISPR And CRISPR-Associated (Cas) Genes Product Introduction1.2 Market Segments1.3 Key CRISPR And CRISPR-Associated (Cas) Genes Manufacturers Covered: Ranking by Revenue1.4 Market by Type1.4.1 Global CRISPR And CRISPR-Associated (Cas) Genes Market Size Growth Rate by Type1.4.2 Genome Editing1.4.3 Genetic engineering1.4.4 gRNA Database/Gene Librar1.4.5 CRISPR Plasmid1.4.6 Human Stem Cells1.4.7 Genetically Modified Organisms/Crops1.4.8 Cell Line Engineering1.5 Market by Application1.5.1 Global CRISPR And CRISPR-Associated (Cas) Genes Market Size Growth Rate by Application1.5.2 Biotechnology Companies1.5.3 Pharmaceutical Companies1.5.4 Academic Institutes1.5.5 Research and Development Institutes1.6 Coronavirus Disease 2019 (Covid-19): CRISPR And CRISPR-Associated (Cas) Genes Industry Impact1.6.1 How the Covid-19 is Affecting the CRISPR And CRISPR-Associated (Cas) Genes Industry

1.6.1.1 CRISPR And CRISPR-Associated (Cas) Genes Business Impact Assessment Covid-19

1.6.1.2 Supply Chain Challenges

1.6.1.3 COVID-19s Impact On Crude Oil and Refined Products1.6.2 Market Trends and CRISPR And CRISPR-Associated (Cas) Genes Potential Opportunities in the COVID-19 Landscape1.6.3 Measures / Proposal against Covid-19

1.6.3.1 Government Measures to Combat Covid-19 Impact

1.6.3.2 Proposal for CRISPR And CRISPR-Associated (Cas) Genes Players to Combat Covid-19 Impact1.7 Study Objectives1.8 Years Considered 2 Executive Summary2.1 Global CRISPR And CRISPR-Associated (Cas) Genes Market Size Estimates and Forecasts2.1.1 Global CRISPR And CRISPR-Associated (Cas) Genes Revenue 2015-20262.1.2 Global CRISPR And CRISPR-Associated (Cas) Genes Sales 2015-20262.2 CRISPR And CRISPR-Associated (Cas) Genes Market Size by Region: 2020 Versus 20262.2.1 Global CRISPR And CRISPR-Associated (Cas) Genes Retrospective Market Scenario in Sales by Region: 2015-20202.2.2 Global CRISPR And CRISPR-Associated (Cas) Genes Retrospective Market Scenario in Revenue by Region: 2015-2020 3 Global CRISPR And CRISPR-Associated (Cas) Genes Competitor Landscape by Players3.1 CRISPR And CRISPR-Associated (Cas) Genes Sales by Manufacturers3.1.1 CRISPR And CRISPR-Associated (Cas) Genes Sales by Manufacturers (2015-2020)3.1.2 CRISPR And CRISPR-Associated (Cas) Genes Sales Market Share by Manufacturers (2015-2020)3.2 CRISPR And CRISPR-Associated (Cas) Genes Revenue by Manufacturers3.2.1 CRISPR And CRISPR-Associated (Cas) Genes Revenue by Manufacturers (2015-2020)3.2.2 CRISPR And CRISPR-Associated (Cas) Genes Revenue Share by Manufacturers (2015-2020)3.2.3 Global CRISPR And CRISPR-Associated (Cas) Genes Market Concentration Ratio (CR5 and HHI) (2015-2020)3.2.4 Global Top 10 and Top 5 Companies by CRISPR And CRISPR-Associated (Cas) Genes Revenue in 20193.2.5 Global CRISPR And CRISPR-Associated (Cas) Genes Market Share by Company Type (Tier 1, Tier 2 and Tier 3)3.3 CRISPR And CRISPR-Associated (Cas) Genes Price by Manufacturers3.4 CRISPR And CRISPR-Associated (Cas) Genes Manufacturing Base Distribution, Product Types3.4.1 CRISPR And CRISPR-Associated (Cas) Genes Manufacturers Manufacturing Base Distribution, Headquarters3.4.2 Manufacturers CRISPR And CRISPR-Associated (Cas) Genes Product Type3.4.3 Date of International Manufacturers Enter into CRISPR And CRISPR-Associated (Cas) Genes Market3.5 Manufacturers Mergers & Acquisitions, Expansion Plans 4 Breakdown Data by Type (2015-2026)4.1 Global CRISPR And CRISPR-Associated (Cas) Genes Market Size by Type (2015-2020)4.1.1 Global CRISPR And CRISPR-Associated (Cas) Genes Sales by Type (2015-2020)4.1.2 Global CRISPR And CRISPR-Associated (Cas) Genes Revenue by Type (2015-2020)4.1.3 CRISPR And CRISPR-Associated (Cas) Genes Average Selling Price (ASP) by Type (2015-2026)4.2 Global CRISPR And CRISPR-Associated (Cas) Genes Market Size Forecast by Type (2021-2026)4.2.1 Global CRISPR And CRISPR-Associated (Cas) Genes Sales Forecast by Type (2021-2026)4.2.2 Global CRISPR And CRISPR-Associated (Cas) Genes Revenue Forecast by Type (2021-2026)4.2.3 CRISPR And CRISPR-Associated (Cas) Genes Average Selling Price (ASP) Forecast by Type (2021-2026)4.3 Global CRISPR And CRISPR-Associated (Cas) Genes Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End 5 Breakdown Data by Application (2015-2026)5.1 Global CRISPR And CRISPR-Associated (Cas) Genes Market Size by Application (2015-2020)5.1.1 Global CRISPR And CRISPR-Associated (Cas) Genes Sales by Application (2015-2020)5.1.2 Global CRISPR And CRISPR-Associated (Cas) Genes Revenue by Application (2015-2020)5.1.3 CRISPR And CRISPR-Associated (Cas) Genes Price by Application (2015-2020)5.2 CRISPR And CRISPR-Associated (Cas) Genes Market Size Forecast by Application (2021-2026)5.2.1 Global CRISPR And CRISPR-Associated (Cas) Genes Sales Forecast by Application (2021-2026)5.2.2 Global CRISPR And CRISPR-Associated (Cas) Genes Revenue Forecast by Application (2021-2026)5.2.3 Global CRISPR And CRISPR-Associated (Cas) Genes Price Forecast by Application (2021-2026) 6 North America6.1 North America CRISPR And CRISPR-Associated (Cas) Genes by Country6.1.1 North America CRISPR And CRISPR-Associated (Cas) Genes Sales by Country6.1.2 North America CRISPR And CRISPR-Associated (Cas) Genes Revenue by Country6.1.3 U.S.6.1.4 Canada6.2 North America CRISPR And CRISPR-Associated (Cas) Genes Market Facts & Figures by Type6.3 North America CRISPR And CRISPR-Associated (Cas) Genes Market Facts & Figures by Application 7 Europe7.1 Europe CRISPR And CRISPR-Associated (Cas) Genes by Country7.1.1 Europe CRISPR And CRISPR-Associated (Cas) Genes Sales by Country7.1.2 Europe CRISPR And CRISPR-Associated (Cas) Genes Revenue by Country7.1.3 Germany7.1.4 France7.1.5 U.K.7.1.6 Italy7.1.7 Russia7.2 Europe CRISPR And CRISPR-Associated (Cas) Genes Market Facts & Figures by Type7.3 Europe CRISPR And CRISPR-Associated (Cas) Genes Market Facts & Figures by Application 8 Asia Pacific8.1 Asia Pacific CRISPR And CRISPR-Associated (Cas) Genes by Region8.1.1 Asia Pacific CRISPR And CRISPR-Associated (Cas) Genes Sales by Region8.1.2 Asia Pacific CRISPR And CRISPR-Associated (Cas) Genes Revenue by Region8.1.3 China8.1.4 Japan8.1.5 South Korea8.1.6 India8.1.7 Australia8.1.8 Taiwan8.1.9 Indonesia8.1.10 Thailand8.1.11 Malaysia8.1.12 Philippines8.1.13 Vietnam8.2 Asia Pacific CRISPR And CRISPR-Associated (Cas) Genes Market Facts & Figures by Type8.3 Asia Pacific CRISPR And CRISPR-Associated (Cas) Genes Market Facts & Figures by Application 9 Latin America9.1 Latin America CRISPR And CRISPR-Associated (Cas) Genes by Country9.1.1 Latin America CRISPR And CRISPR-Associated (Cas) Genes Sales by Country9.1.2 Latin America CRISPR And CRISPR-Associated (Cas) Genes Revenue by Country9.1.3 Mexico9.1.4 Brazil9.1.5 Argentina9.2 Central & South America CRISPR And CRISPR-Associated (Cas) Genes Market Facts & Figures by Type9.3 Central & South America CRISPR And CRISPR-Associated (Cas) Genes Market Facts & Figures by Application 10 Middle East and Africa10.1 Middle East and Africa CRISPR And CRISPR-Associated (Cas) Genes by Country10.1.1 Middle East and Africa CRISPR And CRISPR-Associated (Cas) Genes Sales by Country10.1.2 Middle East and Africa CRISPR And CRISPR-Associated (Cas) Genes Revenue by Country10.1.3 Turkey10.1.4 Saudi Arabia10.1.5 UAE10.2 Middle East and Africa CRISPR And CRISPR-Associated (Cas) Genes Market Facts & Figures by Type10.3 Middle East and Africa CRISPR And CRISPR-Associated (Cas) Genes Market Facts & Figures by Application 11 Company Profiles11.1 Caribou Biosciences11.1.1 Caribou Biosciences Corporation Information11.1.2 Caribou Biosciences Description, Business Overview and Total Revenue11.1.3 Caribou Biosciences Sales, Revenue and Gross Margin (2015-2020)11.1.4 Caribou Biosciences CRISPR And CRISPR-Associated (Cas) Genes Products Offered11.1.5 Caribou Biosciences Recent Development11.2 Addgene11.2.1 Addgene Corporation Information11.2.2 Addgene Description, Business Overview and Total Revenue11.2.3 Addgene Sales, Revenue and Gross Margin (2015-2020)11.2.4 Addgene CRISPR And CRISPR-Associated (Cas) Genes Products Offered11.2.5 Addgene Recent Development11.3 CRISPR THERAPEUTICS11.3.1 CRISPR THERAPEUTICS Corporation Information11.3.2 CRISPR THERAPEUTICS Description, Business Overview and Total Revenue11.3.3 CRISPR THERAPEUTICS Sales, Revenue and Gross Margin (2015-2020)11.3.4 CRISPR THERAPEUTICS CRISPR And CRISPR-Associated (Cas) Genes Products Offered11.3.5 CRISPR THERAPEUTICS Recent Development11.4 Merck KGaA11.4.1 Merck KGaA Corporation Information11.4.2 Merck KGaA Description, Business Overview and Total Revenue11.4.3 Merck KGaA Sales, Revenue and Gross Margin (2015-2020)11.4.4 Merck KGaA CRISPR And CRISPR-Associated (Cas) Genes Products Offered11.4.5 Merck KGaA Recent Development11.5 Mirus Bio LLC11.5.1 Mirus Bio LLC Corporation Information11.5.2 Mirus Bio LLC Description, Business Overview and Total Revenue11.5.3 Mirus Bio LLC Sales, Revenue and Gross Margin (2015-2020)11.5.4 Mirus Bio LLC CRISPR And CRISPR-Associated (Cas) Genes Products Offered11.5.5 Mirus Bio LLC Recent Development11.6 Editas Medicine11.6.1 Editas Medicine Corporation Information11.6.2 Editas Medicine Description, Business Overview and Total Revenue11.6.3 Editas Medicine Sales, Revenue and Gross Margin (2015-2020)11.6.4 Editas Medicine CRISPR And CRISPR-Associated (Cas) Genes Products Offered11.6.5 Editas Medicine Recent Development11.7 Takara Bio USA11.7.1 Takara Bio USA Corporation Information11.7.2 Takara Bio USA Description, Business Overview and Total Revenue11.7.3 Takara Bio USA Sales, Revenue and Gross Margin (2015-2020)11.7.4 Takara Bio USA CRISPR And CRISPR-Associated (Cas) Genes Products Offered11.7.5 Takara Bio USA Recent Development11.8 Thermo Fisher Scientific11.8.1 Thermo Fisher Scientific Corporation Information11.8.2 Thermo Fisher Scientific Description, Business Overview and Total Revenue11.8.3 Thermo Fisher Scientific Sales, Revenue and Gross Margin (2015-2020)11.8.4 Thermo Fisher Scientific CRISPR And CRISPR-Associated (Cas) Genes Products Offered11.8.5 Thermo Fisher Scientific Recent Development11.9 Horizon Discovery Group11.9.1 Horizon Discovery Group Corporation Information11.9.2 Horizon Discovery Group Description, Business Overview and Total Revenue11.9.3 Horizon Discovery Group Sales, Revenue and Gross Margin (2015-2020)11.9.4 Horizon Discovery Group CRISPR And CRISPR-Associated (Cas) Genes Products Offered11.9.5 Horizon Discovery Group Recent Development11.10 Intellia Therapeutics11.10.1 Intellia Therapeutics Corporation Information11.10.2 Intellia Therapeutics Description, Business Overview and Total Revenue11.10.3 Intellia Therapeutics Sales, Revenue and Gross Margin (2015-2020)11.10.4 Intellia Therapeutics CRISPR And CRISPR-Associated (Cas) Genes Products Offered11.10.5 Intellia Therapeutics Recent Development11.1 Caribou Biosciences11.1.1 Caribou Biosciences Corporation Information11.1.2 Caribou Biosciences Description, Business Overview and Total Revenue11.1.3 Caribou Biosciences Sales, Revenue and Gross Margin (2015-2020)11.1.4 Caribou Biosciences CRISPR And CRISPR-Associated (Cas) Genes Products Offered11.1.5 Caribou Biosciences Recent Development 12 Future Forecast by Regions (Countries) (2021-2026)12.1 CRISPR And CRISPR-Associated (Cas) Genes Market Estimates and Projections by Region12.1.1 Global CRISPR And CRISPR-Associated (Cas) Genes Sales Forecast by Regions 2021-202612.1.2 Global CRISPR And CRISPR-Associated (Cas) Genes Revenue Forecast by Regions 2021-202612.2 North America CRISPR And CRISPR-Associated (Cas) Genes Market Size Forecast (2021-2026)12.2.1 North America: CRISPR And CRISPR-Associated (Cas) Genes Sales Forecast (2021-2026)12.2.2 North America: CRISPR And CRISPR-Associated (Cas) Genes Revenue Forecast (2021-2026)12.2.3 North America: CRISPR And CRISPR-Associated (Cas) Genes Market Size Forecast by Country (2021-2026)12.3 Europe CRISPR And CRISPR-Associated (Cas) Genes Market Size Forecast (2021-2026)12.3.1 Europe: CRISPR And CRISPR-Associated (Cas) Genes Sales Forecast (2021-2026)12.3.2 Europe: CRISPR And CRISPR-Associated (Cas) Genes Revenue Forecast (2021-2026)12.3.3 Europe: CRISPR And CRISPR-Associated (Cas) Genes Market Size Forecast by Country (2021-2026)12.4 Asia Pacific CRISPR And CRISPR-Associated (Cas) Genes Market Size Forecast (2021-2026)12.4.1 Asia Pacific: CRISPR And CRISPR-Associated (Cas) Genes Sales Forecast (2021-2026)12.4.2 Asia Pacific: CRISPR And CRISPR-Associated (Cas) Genes Revenue Forecast (2021-2026)12.4.3 Asia Pacific: CRISPR And CRISPR-Associated (Cas) Genes Market Size Forecast by Region (2021-2026)12.5 Latin America CRISPR And CRISPR-Associated (Cas) Genes Market Size Forecast (2021-2026)12.5.1 Latin America: CRISPR And CRISPR-Associated (Cas) Genes Sales Forecast (2021-2026)12.5.2 Latin America: CRISPR And CRISPR-Associated (Cas) Genes Revenue Forecast (2021-2026)12.5.3 Latin America: CRISPR And CRISPR-Associated (Cas) Genes Market Size Forecast by Country (2021-2026)12.6 Middle East and Africa CRISPR And CRISPR-Associated (Cas) Genes Market Size Forecast (2021-2026)12.6.1 Middle East and Africa: CRISPR And CRISPR-Associated (Cas) Genes Sales Forecast (2021-2026)12.6.2 Middle East and Africa: CRISPR And CRISPR-Associated (Cas) Genes Revenue Forecast (2021-2026)12.6.3 Middle East and Africa: CRISPR And CRISPR-Associated (Cas) Genes Market Size Forecast by Country (2021-2026) 13 Market Opportunities, Challenges, Risks and Influences Factors Analysis13.1 Market Opportunities and Drivers13.2 Market Challenges13.3 Market Risks/Restraints13.4 Porters Five Forces Analysis13.5 Primary Interviews with Key CRISPR And CRISPR-Associated (Cas) Genes Players (Opinion Leaders) 14 Value Chain and Sales Channels Analysis14.1 Value Chain Analysis14.2 CRISPR And CRISPR-Associated (Cas) Genes Customers14.3 Sales Channels Analysis14.3.1 Sales Channels14.3.2 Distributors 15 Research Findings and Conclusion 16 Appendix16.1 Research Methodology16.1.1 Methodology/Research Approach16.1.2 Data Source16.2 Author Details

About Us:

QYResearch always pursuits high product quality with the belief that quality is the soul of business. Through years of effort and supports from the huge number of customer supports, QYResearch consulting group has accumulated creative design methods on many high-quality markets investigation and research team with rich experience. Today, QYResearch has become a brand of quality assurance in the consulting industry.

Read more:
CRISPR And CRISPR-Associated (Cas) Genes Market which company is the market leader and how much its sales in 2020 and what it's expected sales for the...

Read More...

Foundation Fighting Blindness Launches Upgraded My Retina Tracker Registry for People with Inherited Retinal Diseases (IRDs) – PRNewswire

Sunday, May 17th, 2020

COLUMBIA, Md., May 15, 2020 /PRNewswire/ -- The Foundation Fighting Blindness, the world's leading organization searching for treatments and cures for inherited retinal diseases, has introduced many improvements and upgrades to its My Retina Tracker Registry. Overall, the upgraded platform makes this best-in-class patient database even easier to use for patients, industry, and investigators who access de-identified data for research studies and clinical trial recruitment. Launched in 2013, more than 15,500 IRD patients are active in the Registry. The patient-driven registry is accessible at MyRetinaTracker.org.

"The My Retina Tracker Registry has been an invaluable resource for both IRD patients and research communities. It provides a secure venue for patients to get on the radar screens of therapy developers both industry and researcher partners who are recruiting for clinical trials and conducting studies using human data," says Brian Mansfield, PhD, executive vice president of research and interim chief scientific officer. "From the start, we have been strongly committed to security of privacy coupled with ease-of-use for both patients and professionals. These enhancements are part of our continual process to maximize the registry's usability and efficiently integrate it with our genetic testing programs."

Highlights of upgrades and enhancements:

The Foundation also offers no-cost genetic testing for those affected with IRDs. The Open Access Genetic Testing Program, allows for any eye care professional in the U.S. to order the no-cost test along with a no-cost genetic counseling session for their IRD patients. Neither membership to My Retina Tracker Registry, nor clinician pre-approval, is needed to participate in the Open Access Genetic Testing Program and receive free testing and genetic counseling.

If a person who is tested chooses to join My Retina Tracker Registry, their data is automatically uploaded into their profile from the genetic testing laboratory.

Current sponsors of the new My Retina Tracker Registry include: The George Gund Foundation, Eloxx Pharmaceuticals, Sofia Sees Hope, AGTC and MeiraGTx. Sponsors of the Open Access Genetic Testing Program include: ProQR, Blueprint Genetics, InformedDNA, Sophia Sees Hope, and The George Gund Foundation.

About the Foundation Fighting BlindnessEstablished in 1971, the Foundation Fighting Blindness is the world's leading private funding source for retinal degenerative disease research. The Foundation has raised more than $760 million toward its mission of accelerating research for preventing, treating, and curing blindness caused by the entire spectrum of retinal degenerative diseases including: retinitis pigmentosa, age-related macular degeneration, Usher syndrome, and Stargardt disease. VisitFightingBlindness.orgfor more information.

Media Contact:Chris AdamsVice President, Marketing & Communications[emailprotected]410-423-0585

SOURCE Foundation Fighting Blindness

http://www.FightBlindness.org

Read the original post:
Foundation Fighting Blindness Launches Upgraded My Retina Tracker Registry for People with Inherited Retinal Diseases (IRDs) - PRNewswire

Read More...

Prevent Blindness Offers New Educational Resources on IRD’s, Importance of Genetic Testing and Services – InvisionMag

Sunday, May 17th, 2020

(PRESS RELEASE) CHICAGO In order to help patients with Inherited Retinal Diseases (IRDs) receive an accurate diagnosis through genetic testing, Prevent Blindness, the nations oldest volunteer eye health organization, is embarking on a new awareness initiative to educate the public on IRDs, a group of genetic disorders that can cause severe vision loss or total blindness. A recent editorial noted that IRDs are the leading cause of vision loss in persons between 15 and 45 years of age- impacting one in every 2,000 people.

To continue the Prevent Blindness mission of preventing blindness and saving sight, the group has declared May 17-23, 2020 as Inherited Retinal Disease Genetic Testing Week. As part of this initiative, Prevent Blindness has created a dedicated webpage (to go live on May 15, 2020) with no-cost educational resources on IRDs, providing detailed information on risk factors, therapy and research options, financial assistance services, the importance of genetic testing, and more. Shareable social media graphics on IRDs are also available. Development of these new resources was supported by a donation from Spark Therapeutics, a gene therapy company striving to challenge the inevitability of genetic disease.

The most common types of IRDs include:

All those diagnosed with IRDs should work with their healthcare professional to develop a disease management plan tailored to the patients needs.

Patients with suspected IRDs are encouraged to participate in genetic testing, even those who were tested more than five years ago and did not receive a definitive result. According to the National Institutes of Health, genetic testing is a type of medical test that identifies changes in chromosomes, genes, or proteins. The results of a genetic test may provide a detailed diagnosis which confirms or rules out most suspected genetic conditions and the test can help determine a persons chance of developing or passing on a genetic disorder to their children. Free genetic testing is now available from select organizations and commercial businesses, including through the ID YOUR IRD program.

Inherited retinal diseases can have a significant impact on the quality of life for patients, including affecting the ability to work and live independently, said Jeff Todd, president and CEO of Prevent Blindness. Fortunately, today there are more therapies being researched than ever before. We encourage patients and their caregivers to educate themselves on steps that can be taken today to save sight for tomorrow.

As a leading gene therapy company with a strong commitment to genetic testing for the IRD community, Spark Therapeutics is pleased to support the Prevent Blindness inaugural IRD Genetic Testing Week, said Dan Chung, DO, MA, ophthalmology therapeutic area leader, Spark Therapeutics. We encourage patients living with IRDs and caregivers to pursue genetic testing in order to receive a true, genetic diagnosis.

For more information on IRDs and genetic testing for vision issues, please call Prevent Blindness at (800) 331-2020 or visit here. For a listing of vision care financial assistance programs in English or Spanish, visit here.

Read more here:
Prevent Blindness Offers New Educational Resources on IRD's, Importance of Genetic Testing and Services - InvisionMag

Read More...

Legends of Tomorrow: Saras Blindness & Superpower Explained – What It Means – Screen Rant

Sunday, May 17th, 2020

Legends of Tomorrow season 5, episode 11, "Ship Broken" affirmed Sara Lance's superpower and the price she had to pay to take advantage of it.

Warning: SPOILERS for Legends of Tomorrow, Season 5, Episode 11, "Ship Broken."

Legends of Tomorrowseason 5, episode 11, "Ship Broken" confirmed that Sara Lance had developed the power to see the future, but revealed that she had also lost her sight. Interestingly enough, this places Sara within two categories of hero common to both superhero comics and mythology in general; the blind seer and the blind warrior.

The youngest daughter of Quentin and Dinah Lance, Sara Lance is perhaps the most popular of the original characters created for the Arrowverse. Whereas Oliver Queen spent "five years in Hell" learning the skills he would later use to save his city, Sara Lance spent six years struggling to survive as a captive of the mad scientist Anthony Ivo and training as an assassin under the tutelage of Ra's Al Ghul. She was later given the rare opportunity to leave the League of Assassins, returning home to become a protector of the innocent as Canary. Following her death and resurrection, she took on the alias White Canary and became one of the founding members of the Legends of Tomorrow, eventually becoming the Captain of the Waverider when Rip Hunter left the team.

Related: Legends of Tomorrow Reveals How Heatwave Funds The Arrowverse Team

Throughout all of this, Sara has held her own against metahumans and magicians alike, despite lacking any superpowers of her own. That changed in the Legends of Tomorrow episode "The Great British Fake Off," where Sara seemed to start seeing events play out just before they happened. This occurred twice before Sara lapsed into a coma. She woke up early on in the following episode, "Ship Broken," but quickly realized that she had been struck blind - an unfortunate consequence for being able to see the future.

Sara's precognition took on a new form in this episode, giving her horrific visions of her teammates's deaths whenever she touched anyone's hand, ala Johnny Smith in The Dead Zone. By the end of the episode, Sara had learned how to focus this ability, shifting her perspective to check on specific people while holding another person's hand. Through this, she was able to witness and then avert Mick Rory's death by hellhound while holding hands with John Constantine.

It's worth noting that the loss of her sight has not robbed Sara Lance of her ability to fight. When Sara protested Constantine's statement that he was glad he had her to protect him while facing the hellhound, he reminded her that she was blind, not deaf. Trained to fight while blindfolded, Sara was able to backflip over a prone Constantine and deliver an impressive midair kick to the hellhound as it tried to pounce on her.While she may not be on par with Daredevil just yet, Sara more than proved her worthiness to continue leading the Legends of Tomorrow.

More: Why Legends of Tomorrow Keeps Recruiting Its Villains To The Team

The Flash Theory: Barry Was Replaced In The Season 6 Finale

Matt Morrison has been writing about comics since before the word"blogging" was coined. He got his start writing for thelegendary DC Comics digital fanzine Fanzing,before receiving his own column, The Mount. Since then he has gone onto write for over a dozen websites, including 411Mania, ComicsNexus and The Cult of Nobody. He holds both an MS in InformationScience from the University of North Texas and a BFA from theUniversity of Texas at Arlington. Known as a font of comic bookhistory trivia, he has delivered lectures on the history of AmericanComic Books, Japanese Manga and Cosplay at over a dozen conventionsand served as an Expert In-Residence for a course on Graphic Novelsfor Librarians at the University of North Texas. In addition to hiswork for Screen Rant, Matt is currently the Managing Editor ofKabooooom.com, the housecritic of Explore The Multiverse and writes reviews for NoFlying, No Tights a graphic literature and anime review siteaimed at teachers and librarians. He also maintains a personal blog My Geeky Geeky Ways which hosts his extensive episode guide for the television seriesmaking up The Arrowverse as well as hiscomedic Lets Play videos. What little spare time he has isdevoted towards acting, role-playing, movie-riffing and sarcasm. Youcan follow his adventures on Twitter, @GeekyGeekyWays.

See original here:
Legends of Tomorrow: Saras Blindness & Superpower Explained - What It Means - Screen Rant

Read More...

What is giant hogweed? How to identify the invasive and toxic plant which can cause burns and even blindness – inews

Sunday, May 17th, 2020

NewsEnvironmentThe Canal and River Trust spends nearly 100,000 a year trying to control giant hogweed and Japanese knotweed

Wednesday, 13th May 2020, 9:20 am

After being introduced into Britain in the early 19th century from central Asia as an ornamental plant, it began growing along canals and rivers. However, in recent years it has appeared in streets and gardens, causing experts to worry that because its pretty and looks like cow parsley, or common hogweed, children may mistake it for something harmless.

If the sap gets rubbed into the eyes it can cause blindness. After contact with the plant, the burns can last for several months and the skin can remain sensitive to light for many years, and the NHS says anyone who touches giant hogweed should wash the affected area with soap and water, and keep it covered.

Growing out of control

Guy Barter, chief horticulturist at the Royal Horticultural Society, said that flooding this year may have carried seeds to new areas, where warm weather has helped the plants grow to at least 2 metres tall, and sometimes up to 5 metres.

Most people know about foxglove and deadly nightshade, he says. But not as many know about giant hogweed. Co-ordinated action is the only way to get rid of it. In the 1990s there was very little of it. The proliferation has got worse everyyear.

The Canal and River Trust spends nearly 100,000 a year trying to control giant hogweed and Japanese knotweed. Plant tracker the Environment Agencys database of invasive, non-native plants reports hundreds of sightings across all of the UK, from Inverness to Kent.

Agonising burns

Dean Simmons was left with agonising body burns in 2015 after brushing against the weed in Taunton, Somerset. I was out fishing and didnt see it until it was too late, he told the BBC at the time, and a day later I was on morphine.

There have since been reports of adults and children hospitalised with third-degree burns.

So, how to spot it? Giant hogweed has large leaves, spotted leaf stalks and a hollow, reddish-purple stem with fine spines that make it appear furry.

Giant hogweed is one of several UK plants to steer clear of. As well as deadly nightshade and the spiky pink and purple foxglove, poison hemlock can also be fatal if ingested. The yellow-and-green plant lords and ladies also has severely poisonous berries but if put on the tongue, they leave an acrid taste as a warning.

Original post:
What is giant hogweed? How to identify the invasive and toxic plant which can cause burns and even blindness - inews

Read More...

Giant Hogweed and Wild Parsnip: Do Not Touch! – Steuben Courier

Sunday, May 17th, 2020

Giant Hogweed (Heracleum mantegazzianum) is a large plant, but although grand and showy in its appearance, it is an invasive plant that you dont want to touch. Also in the same family,Apiaceae the carrot family, is wild parsnip (Pastinaca sativa), another invasive species to avoid. Both plants contain chemicals that can cause a toxic skin reaction when humans encounter the plants sap.

Furanocoumarins, when combined with sunlight, can cause phytophotodermatitis, a serious skin inflammation. The chemical prevents the skin from protecting itself against sunlight, which can lead to a severe sunburn. The reaction can be as mild as skin discoloration or as severe as large, painful blisters. The effects of giant hogweed can be much worse than that of wild parsnip, with some blisters similar to third-degree burns, permanent scarring, discoloration of the skin, increased sensitivity to sunlight that may last for years, and contact with the eyes could lead to blindness.

Giant hogweed was introduced to the United States in the early 1900s. as an ornamental. One of the first plantings was in gardens near Highland Park in Rochester. It escaped cultivation and has now become established in the Northeast and parts of Canada.

Characteristics:

White flowers clustered into an umbrella-shaped flower cluster, up to 2.5 feet across, blooms between June and July (note: plant generally produces a flowering stalk in 3 to 5 years but can take up to 8 years or more)

Between 7 to 14 feet tallwith huge leaves, incised and deeply lobed, up to 5 feet across

Stems are green with purple splotches and coarse white hairs, 2-4 inches in diameter

Seeds are dry, flattened, oval and approximately 3/8-inch-long and tan with brown lines

Except for its towering size, giant hogweed can easily be mistaken for other umbrel plants.

If you see Giant Hogweed, keep your distance, and take high-resolution photos of the entire plant, stem, leaves, flowers and/or seeds. Photos and detailed directions to the infestation can be emailed to DEC at ghogweed@dec.ny.gov or contact your local Cornell Cooperative Extension office for assistance with identification.

DEC crews visit each confirmed infestation site of giant hogweed and use an appropriate control method for the size of infestation and location. This service is free of charge to the landowner. Sites are visited each year until the plants are eradicated. For sites to be monitored and controlled, the landowner must give annual permission.

Wild Parsnip is native to southern and central Europe and was possibly brought to North America as a root crop by colonists as early as the 1600s. It has become established throughout the northern United States and southern Canada.

Characteristics:

Yellow flowers clustered into an umbrella-shaped flower cluster, 4-6 inches wide, blooms between May to mid-July (note: flowering usually occurs during the second year of growth)

Between 2 to 5 feet tall with yellowish-green leaves with 5 to 15 toothed and variably lobed leaflets

Stems are yellowish-green with vertical grooves

Seeds are flat, brown, and slightly winged

Both plants can be found growing on roadsides, fields, pastures, along trails, any place where the soil has been disturbed, and along streams and rivers.

If you see Wild Parsnip, manual removal of plants can be effective for new infestations and small areas. When removing plants, wear gloves, long-sleeved shirts, pants, boots, and eye protection to prevent contact with the sap. Synthetic, water-resistant materials are recommended. Before the plant going to seed, cut the root 1-2 inches below the soil or pull by hand. If removing the plants after they have gone to seed, cut off the seed head and place it in a plastic bag. Leave the bags in the sunlight for one week to kill the seeds before disposal. Mowing only after it has flowered, but before it goes to seed, can kill the plant. When mowing, take precautions to prevent sap from contacting skin and eyes. Clean all protective clothing, gear, tools, and equipment thoroughly. Herbicides such as glyphosate or triclopyr can be applied as spot treatments; follow product labels carefully. Monitor the area long-term for seedlings emerging from the seed bank.

What to do if you come in contact with these plants?Immediately wash the area with soap and COLD water and keep the area away from sunlight for 48 hours. If a reaction occurs, see a physician.

The rest is here:
Giant Hogweed and Wild Parsnip: Do Not Touch! - Steuben Courier

Read More...

Uzbekistan: Andijan blindness slows transition to era of openness, experts say – Eurasianet

Sunday, May 17th, 2020

Fifteen years have elapsed since the worst bout of bloodletting that Uzbekistan has seen in its post-independence history, but still the authorities, even under the rule of self-styled reformer President Shavkat Mirziyoyev, appear uninterested in pursuing a thorough and transparent investigation.

The uprising in the ancient Ferghana Valley bazaar city of Andijan which began on May 13, 2005, came on the heels of a wave of arrests of local businessmen tied to another one by their strong Islamic faith.

The thousands that took their positions on the citys Bobur Square were almost all unarmed citizens, although they also included some gunmen who had been sprung overnight from the local prison. After days of tension, then President Islam Karimovs government sent in heavily armed troops, who indiscriminately opened fire on the crowd.

There is no consensus on the exact number of fatalities as the authorities swiftly squelched any pleas to conduct an independent investigation. The official figure is 187 dead. Rights activists believe the real figure is many times greater.

Although the current political elite in Tashkent does not openly talk about this, the disastrous economic situation and political consequences brought on by the Andijan massacre and its aftermath in large part contributed to President Mirziyoyevs determination to break with the Karimov legacy and begin certain reforms, said Steve Swerdlow, a human rights lawyer and Central Asia expert.

There was a slight shift in the official tone earlier this year when Deputy Prosecutor General Svetlana Artykovagave an interviewto a local outlet,Qalampir.uz, in which she appeared to concede that excessive force was deployed. The remarks made by Artykova, who was the spokeswoman for the prosecutors office in May 2005, could only have been made with approval from above.

When asked if weapons were used by government forces against civilians, Artykova answered that there had been no clear coordination between troops and the national leadership and that this was why a certain number of citizens died during the rally.

Some officials found responsible for unlawful killing were convicted and some were already out of prison, Artykova claimed. This was the first time any Uzbek official has alleged that any officials were imprisoned for their involvement in the Andijan events.

The idea that government troops would have acted with such force upon their own initiative defies credibility, however.

Indeed, documentaries produced for state television since Mirziyoyev came to power have sought to whitewash the actions of senior security officials, including then Interior MinisterZokir Almatov.After the Andijan events, Almatov was included on a list of Uzbek officials sanctioned by the European Union and the United States. Under international pressure, Karimov finally caved and dismissed Almatov.

But Almatov has since beenrehabilitatedand beendraftedby Mirziyoyev to assist in reforming the police force.

In the wake of Andijan, the repression of devout Muslims, whose presence was especially pronounced in the Ferghana Valley, only escalated. Many rights activists were also hounded out of Uzbekistan. Numerous international organizations were forced to shutter.

Although there have been many improvements in those areas, Kamoliddin Rabimov, a political migr residing in France, believes the Mirziyoyev administration is unlikely to wish to revisit what happened in May 2005.

For the political elite, especially for the security forces, any such step would be considered a source of destabilization. And for the public, the issue of the Andijan tragedy has been, and remains to be, a very sensitive, painful matter, Rabimov said.

Ravshan Nazarov, a historian in Tashkent, told Eurasianet that there continues to be a split in perceptions about what actually happened in Andijan. Many hold the opinion that the uprising was the entirely the work of extremists and terrorists a view that has been eagerly promoted by state-funded action movies, at least one of which is shown as in-trip entertainment on trains running between Tashkent and Andijan. Another camp recalls the events as just another instance of cruel suppression of a peaceful demonstration.

It is this polarized set of perceptions that makes a proper study of the uprising so necessary, said Nazarov

A serious and thorough analysis of all available materials and documents on the events of 2005 remains to be done. It is necessary to talk directly with participants and witnesses of those events, he told Eurasianet.

Such a process would in any event only be in keeping with Uzbekistans pledges to bodies like theUN Human Rights Committee and Committee Against Torture to enable an impartial and international investigation.

There is more at stake than just fresh insight into a specific set of events.

Truth-telling and public discussion about the Andijan massacre are deeply important 15 years after the events, said Swerdlow. Andijan in many ways was the defining event of the Karimov era. It is necessary to comprehend and study it in an open format for national healing. Understanding the painful history of Andijan will ultimately help Uzbekistan make a transition to a more open and democratic society.

Excerpt from:
Uzbekistan: Andijan blindness slows transition to era of openness, experts say - Eurasianet

Read More...

Quarantine books: Your essential end-of-the-world reading list – Los Angeles Times

Sunday, May 17th, 2020

When the seas of life get rough, some readers look for escape, while others dive right in. So it is during the pandemic, when many book lovers are turning toward apocalyptic fiction.

A modern classic of the genre is Emily St. John Mandels Station Eleven, which tells the story of a nomadic group of entertainers in the years after a flu has destroyed civilization. I would not recommend reading Station Eleven in the middle of a pandemic, Mandel told the L.A. Times in an interview.

Yet many people are doing just that: The book is selling briskly just as Mandels new novel of financial disaster, The Glass Hotel, settles into the Los Angeles Times bestseller list. Mandel joins the L.A. Times Book Club on May 19 for a virtual discussion of these two eerily timely novels.

In advance of Mandels appearance, we asked her and a few other authors to help us put together an end-of-world reading list.

Mandel called the 1961 Hugo Award winner an interesting and somewhat haunting story. It was the first post-apocalyptic book I read, and reading it made me think for the first time about what a post-apocalyptic world might look like.

Susan Orlean, author of The Library Book, suggested the classic dystopian novel, which played a role in her nonfiction bestseller about the 1986 fire that closed the Los Angeles Central Library for seven years. Orlean also mentioned A Canticle for Leibowitz.

T.C Boyle, author of the upcoming Talk to Me, called Fiskadoro a poetic fever dream which takes place in the Florida Keys a generation after a nuclear war has destroyed most of civilization and rendered vast territories uninhabitable. The novel opens up the reader to what culture is, what it means to its constituency, and how it draws from the traditions of the past in order to create a rationale for the present.

Marlon James, winner of the 2020 L.A. Times Ray Bradbury Prize, described the Frankenstein authors later work as the original speculative novel. Funny enough, it was a plague I was like, Damn, girl. The original dystopian novel got it right! He also mentioned The Handmaids Tale, by Margaret Atwood.

The vivid, unusual, stirring characters make it a piquant and often enjoyable read despite the pointed bleakness of the setting, Malka Older, author of Infomocracy, said of Solomons debut science fiction novel. Its structurally and thematically daring and manages to include a little bit of hope while leveling a devastating critique at racism and fascism.

Lessings writing is so perfect and full of beautiful details that her apocalypse feels inextricably linked to the rest of her narrative, said Charlie Jane Anders, author of The City in the Middle of the Night. I feel like people dont read Lessing as much as they did maybe 20 years ago, and this makes me incredibly sad of all the 20th century lit authors, shes the one whose work is the most relevant and timeless in 2020. Anders also recommended Cats Cradle, by Kurt Vonnegut, The Fifth Season, by N. K. Jemisin and Jos Saramagos Blindness.

Wil Wheaton, actor and author of Just a Geek, suggested this three-book anthology edited by John Joseph Adams and Hugh Howey. The collection tells stories from three distinct periods in the apocalypse: The end is nigh, the end is now, and the end has come. While there are fantastic stand-alone stories in each volume, for a reader who wants to take the whole ride, there are some extremely rewarding tales. Standouts include Charlie Jane Anders, Scott Sigler and Seanan McGuire.

Aimee Liu, author of the new novel Glorious Boy, cited the Pulitzer Prize-winning tales unflinching humanity in the face of horror and uncertainty, all amplified by McCarthys refusal to name the precise cause, date, or nature of Earths collapse. Liu also mentioned The Book of Aron, by Jim Shepard.

Im a Shakespeare buff, and I thought it was terribly inventive, said Jess Walter, author of Beautiful Ruins and the upcoming Cold Millions. I admired her deft writing touch and the way she moved back and forth in time. Walter also mentioned Oryx and Crake, by Margaret Atwood, and Cats Cradle, by Kurt Vonnegut.

Alex Espinoza, author of Cruising, is another fan of Saramagos story of an epidemic of blindness that sweeps through an unidentified city. The novel focuses on a group of strangers who are among the first to get infected and are quarantined in a filthy, crowded asylum where they must band together in order to survive. A terrifying and timely story.

Wolk has been a senior correspondent for Reuters and NBC News, among other publications.If you go: Book ClubEmily St. John Mandel, author of Station Eleven and The Glass Hotel, joins the L.A. Times Book Club in conversation with reporter Carolina A. Miranda.

When: 7 p.m. May 19

Where: Free virtual event livestreaming on the Los Angeles Times Facebook Page and YouTube.

More info: latimes.com/bookclub

View original post here:
Quarantine books: Your essential end-of-the-world reading list - Los Angeles Times

Read More...

Seva Foundation Celebrating Wavy Gravy’s 84th Birthday With Archival Video Release – JamBase

Sunday, May 17th, 2020

Seva Foundation will celebrate 1960s counter-culture icon Wavy Gravys 84th birthday with a Quarantine Concert featuring previously unreleased archival videos from past Seva benefit concerts spanning 2007 to 2019. Bob Weir, David Crosby & Graham Nash, Bonnie Raitt & Ruthie Foster, Hot Tuna, Zero and many more musicians will be part of the online event.

Other acts that are part of Sevas Quarantine Concert include Ani DiFranco, Blind Boys Of Alabama, Chris Robinson, Dr. John & Buffy Sainte-Marie, Jackson Browne, Jason Mraz, New Riders Of The Purple Sage, Poor Mans Whiskey, Roy Rogers & Carlos Reyes, Steve Kimock, Rising Appalacia and Steve Earle. The event will be able to be streamed between May 14 and 17. Follow this link for more information.

The Berkeley, California-based Seva Foundation is a global nonprofit eye care organization that transforms lives and strengthens communities by restoring sight and preventing blindness preventing and treating blindness and other visual impairments. The Grateful Dead performed at the first Seva benefit concert in 1979.

Read the original here:
Seva Foundation Celebrating Wavy Gravy's 84th Birthday With Archival Video Release - JamBase

Read More...

World Hypertension Day 2020: Know the remedies for defeating this silent killer – Jagran English

Sunday, May 17th, 2020

New Delhi | Jagran Lifestyle Desk: World Hypertension Day is observed on May 17 every year to increase the awareness about this ilent killer and help people realise that Hypertension or high blood pressure is a preventable and controllable condition.

Increasing the awareness about the condition -- where the blood pressure is consistently more than 140/90mm/Hg -- is necessary given the lack of knowledge among the people about the 'silent killer' as the symptoms often go unnoticed during the early phase.

Dr P Venkata Krishnan, Internal Medicine, at Paras Hospital, Gurugram, as quoted by news agency ANI, explains that the condition can be considered as the cause of many NCDs -- heart attacks, kidney failure, stroke, and also damage to eyes.

"Its prevalence is widespread with different studies concluding anywhere between one third and 50 per cent of the population suffering from hypertension. While 90 per cent of the cases of high BP is idiopathic, in 5 per cent of the cases, it is caused by underlying conditions of heart, thyroid and kidney diseases or other illness," said Dr Krishnan.

The major concern surrounding the condition is that of not showing any visible symptoms, and hence difficult to detect it via regular health and BP check-up. In fact, the doctor says that in most people, it is diagnosed during a regular check-up.

"Treating hypertension requires a combination of dietary and lifestyle modifications as well as medicines under medical supervision. Taking proactive steps such as a decrease in the consumption of junk food, managing stress, and regular exercise are important not just in the management of hypertension but also its prevention," he concluded.

Highlighting another viewpoint around the condition, Dr Parul Katiyar, Fertility Consultant, Nova IVF Fertility, said that hypertension can also adversely affect fertility, especially in men.

"Various studies have suggested that hypertensive men tend to have low semen volume, sperm count and motility. Some of the antihypertensive medications have been linked to poor semen volume and quality and their side-effects also include retrograde ejaculation and erectile dysfunction," remarked Dr Katiyar.

The doctor also emphasised that hypertension can be managed by bringing certain changes in the lifestyle and also intake of the right medication can result in improvement in impaired semen and erectile dysfunction.

Talking about chronic hypertension during pregnancy, Dr Manisha Ranjan, Consultant Obstetrician and Gynaecologist, Motherhood Hospital, Noida, said that the condition has been associated with a number of adverse pregnancy outcomes, including premature delivery, fetal growth restriction, fetal death, placental abruption, and cesarean delivery.

"Sometimes, the onset of high blood pressure during pregnancy may be a sign of preeclampsia, a condition in which high blood pressure occurs exclusively in pregnancy. Therefore, even if your chronic high blood pressure is under control before you are pregnant, you may later develop preeclampsia, as well," she added.

The doctor further recommended inducing labour before the patient's due date in order to prevent any pregnancy complications. In some cases, cesarean birth is also recommended.

"So, it becomes imperative that one should manage their high blood pressure during pregnancy by eating a healthy diet, reducing sodium intake, taking medications properly, and staying physically active," the gynaecologist explained.

Referring to the prevailing coronavirus crisis, Dr Manjeetha Nath Das, Internal Medicine, Columbia Asia Hospital, said that the condition has emerged as serious comorbidity, especially for the elderly.

"Every third Indian grown up has this disease. Its high prevalence makes all these people vulnerable to coronavirus, which may affect them more severely than those who are not hypertensive and increase the chances of death," said Dr Das.

"Therefore, our aim should be to check the number of new people who get hypertensive and help the hypertensive to manage their condition better. The disease also increases the risk of heart attack, stroke, kidney failure, and blindness significantly," the doctor said.

Dr Das further recommended proper screening of hypertension for anyone over the age of 35 years. "Besides, right from childhood, people should be encouraged to live a healthy and active lifestyle with less sugar and fat intake and minimum 30-minute of activity daily," Dr Das added.

(With ANI Inputs)

Posted By: Talib Khan

Here is the original post:
World Hypertension Day 2020: Know the remedies for defeating this silent killer - Jagran English

Read More...

IAN MANN REVIEWS | Getting the jump on problems before they happen – Fin24

Sunday, May 17th, 2020

Upstream: The quest to solve problemsbefore they happen, by DanHeath

Picnicking beside a river, you see a child floatingdown, in danger of drowning. You and your friend dive in and save her, only tosee another coming down, and another and another. Suddenly you see your friendclimb out the river and start running. "Where are you going?"

"I am going to sort out the person who isthrowing children in the river!"

Author Dan Heath uses the word upstream forefforts intended to prevent problems before they happen.

"So why do our efforts skew so heavily towardreaction rather than prevention?" he asks. Primarily, because the furtherupstream we go back, the more complex the solution. It is easier to call HR torecruit a new executive than it is to ensure that the organisation is a deeplysatisfying place to work.

The US will spend billions more recovering from thecoronavirus because they slashed funding for Centers of Disease Control and Prevention.And similar examples abound.

"My goal in this book is to convince you thatwe should shift more of our energies upstream," Heath explains.

There are three forces that push us downstream,impeding our ability to prevent problems.

The first is what Heath calls problem blindness,the response to problems that is similar to the way we treat the weather there is nothing we can do about it.

The second is that no one takes ownership of theproblem. Stanford researchers, in a paper exploring this sense of reluctance,wrote "what often prevents people from protesting is not a lack ofmotivation to protest, but rather their feeling that they lack the legitimacyto do so."

The third is tunnelling, where people react toproblems rather than prevent them. Tunnelling confines us to short-term,reactive thinking. In the tunnel, theres only forward. When people experiencescarcityof money or time or mental bandwidththe harm is not that the bigproblems crowd out the little ones. The harm is that the little ones crowd outthe big ones.

If upstream thinking is so obviously correct andunequivocally more effective in eliminating recurring problems, why is it sorare? Heath identifies seven significant barriers to upstream thinking andprovides solutions from lessons learned from real world successes.

Heaths three forces described above, and the sevenbarriers (of which I will describe some below) are the same whether you lead afor-profit-business, a public benefit organisation or a government department.

How will you unite all theright people who are needed to solve the problem?

In 1998, 42% of Icelandic 15- and 16-year-olds hadbeen drunk in the previous 30 days. Almost a quarter smoked cigarettes daily,and 17% had already tried cannabis. Among 22 European countries, Icelandic teenagershad the second-highest rate of accidents or injuries related to substance abuse.Todays Icelandic teenagers have grown up in a country where substance abuse islargely absent.

As in many upstream efforts, the success wasachieved by surrounding the problem, recruiting a multifaceted group ofpeople and organisations, united by a common aim "Drug-free Iceland".

The campaign team solicited help from anyone whowas willing to assist: researchers, policymakers, schools, police, parents,teenagers, singers/musicians, government agencies, private companies, churches,sports clubs, athletes, and media members.

Surrounding the problem with the right people and aligningtheir efforts toward preventing specific instances of that problem, was theirsolution.

Who would need to be involved in your organisation?

How will you change the system?

"Every system is perfectly designed to get theresults it gets."

Whether the results are good or bad, the systemthrough which the results are achieved is a complete success.

In 1967, 5 people died for every 100 million milesdriven. Fifty years later, fewer drunk drivers better roads, seat belts,airbags and better braking technologies, reduced that number to 1 death per 100million miles driven. The vastly improved system happened with no centralplanner. Thousands of people, safety experts, transportation engineers andMothers Against Drunk Driving, tweaked the system so that millions of people aresafer.

Identifying the systems that need to change is criticallyimportant.

How will you get early warning ofthe problem?

When everything is cause for alarm, nothing iscause for alarm.

The value of an early warning depends on whetherthe warning gives sufficient time to respond. A car tyre that gives a 30-secondadvance warning of a blowout, might save your life. A half-second warning isworthless.

LinkedIn discovered that the churn rate forcustomers of their flagship product for recruiters was roughly 30%. On further investigationthey found that customers who used the product in the first 30 days were fourtimes more likely to continue using LinkedIn. So, they started using all theresources they had been using to save customers, to onboard them properly sothey become users immediately.

How will you know youresucceeding?

What counts as success? If my laptop broke and youfix it, thats victory. With upstream efforts, success is not alwaysself-evident and is often misleading.

Consider a team that applauds itself for scoringmore runs. Is that because every team in the league is scoring more too,because bowling talent has declined? The team that doubled its run rate barelywon any more games, which doesnt align with their goal.

If the short measures runs starts becoming the goal,players under pressure may start cheating. Here, succeeding with the measuremakes a mockery of the goal. Care must be taken which factors really measuresuccess.

How will you avoid doing harm?

Systems are complicated. One need only consider theban of single use plastic bags that damage the waterways.

An estimated 100 billion bags that may not degradefor hundreds of years, are used annually just in the US. Paper bags andreusable bags are far better than plastic ones from the perspective of keepingwaterways clean, but they are worse in other ways.

A UK Environment Agency study calculated the "peruse" effects of different bags on climate change. You need to use a paperbag 3 times and a cotton reusable bag 131 times to be on par with plastic bagsoverall effect on the environment. Manufacturing paper bags and cotton reusablebags causes more air and water pollution than plastic, and they are much harderto recycle.

Is protecting waterways and marine life our goal,or making the whole environment better?

Systems cant be controlled, but they can bedesigned and redesigned. We need to rely on careful experimentation, guided byfeedback loops. We should think very carefully before proceeding where systemsare involved. Upstream work hinges on an attitude of care and humility.

Who will pay for what does nothappen?

A person will pay if they will reap the rewards andwhat comes out of the pocket goes back in. But what if many units in the organisationor country will benefit, unequally? Getting funding for many pockets is acoordination nightmare.

In the case of climate control, those who areresponsible for the problem (wealthy countries,) require a contribution in cashor kind from poor countries who benefit from the solution, but did little tocause the problem.

Not considering these questions will make upstreamsuccess ever harder. Considering them may go a long way to improve youroperations and I cannot think of any time when that consideration is morenecessary.

I consider this the most useful book I have read inyears. It reads easily and is rich with examples and nuances.

Readability Light--+-- Serious

Insights High +---- Low

Practical High -+--- Low

*Ian Mann of Gateways consultsinternationally on strategy and implementation, is the author of Strategy thatWorks and a public speaker. Views expressed are his own.

See the original post:
IAN MANN REVIEWS | Getting the jump on problems before they happen - Fin24

Read More...

Reach Ramadan Challenge: how you can raise money for river blindness on TikTok – The National

Friday, May 15th, 2020

You can now do your bit for charity this Ramadan by creating a video on social networking platform TikTok.

The video-sharing service has joined the Reach Campaign, an Emirates Red Crescent-organised drive that targets neglected tropical diseases, as its latest media partner. TikTok has pledged to donate $2 (Dh7) for every video created on the app, up to a maximum of $100,000.

The Reach Campaign launched in January and uses the theme Give 2, Save 2 meaning that a Dh2 donation is enough to provide medicine and treatment to protect one person against both diseases for an entire year.

During Ramadan, however, the campaign set a goal of protecting one million people from river blindness over the course of the holy month.

TikTok users can contribute by creating videos using three special interactive "Reach Campaign stickers", or donating directly to the cause through links on the campaigns in-app landing page.

TikTok will also run in-app advertisements shedding light on river blindness, and has encouraged several high-profile public figures to take part in the challenge.

Social media influencers Max of Arabia, Khalid and Salama Al Ameri, Abas, and Mona Sheikh have so far created #ReachTheEnd videos.

More than 200 million people worldwide require treatment for river blindness, one of the leading causes of preventable blindness. It is caused by repeated bites by black flies that live near flowing water.

Like many neglected tropical diseases, river blindness disproportionately affects the worlds most vulnerable people, trapping their families in cycles of poverty. Most of the cases are found in 31 countries in sub-Saharan Africa.

"We are excited to launch a new element to the campaign in collaboration with an innovative partner such as TikTok. Allowing the community to participate creatively while helping reach the end of river blindness has truly inspired users to join our campaign.

"We are honoured to see the inventive ways people continue to show their support from the comfort of their own homes," Nassar Abdul Raouf Al Mubarak, managing director of the Reach Campaign said.

In addition to TikTok videos, the month-long Reach Ramadan campaign follows a simple three-step challenge: the community is encouraged to donate by either texting GIVE to 2424, visiting the Reach the End website, or posting a selfie on social media making a "V for victory over river blindness" sign with their hands, and challenging friends and family to do the same by by tagging them.

Updated: May 12, 2020 05:15 PM

Originally posted here:
Reach Ramadan Challenge: how you can raise money for river blindness on TikTok - The National

Read More...

Intravitreal IVT Injectable Market Worth Will Reach US$ 4350 Mn According To Forecast By 2028 – Cole of Duty

Friday, May 15th, 2020

Retinal diseases contributing heavily to the demand growth of intravitreal (IVT) injectables

Hereditary retinal diseases is the major cause of visual loss. Macular degeneration, Diabetic Retinopathy is the important and prominent cause of blindness.

According to Genentech Retinal disease report, around 11 million US population are affected with age-related macular degeneration, 7.7 million people are affected with diabetic retinopathy and around 1.1 million population are affected with retinal vein occlusions.

Get Sample Copy of Report @ https://www.persistencemarketresearch.com/samples/25906

Company Profiles

Anti-VEGF intravitreal (IVT) injectables medication is most likely use to treat retinal disorders. Increasing prescription of anti-VEGF anticipate the growth of the intravitreal (IVT) injectables market. Many manufacturers aims to develop drugs with anti-VEGF inhibitor, as a result leading to an increase in the demand for intravitreal (IVT) injectables.

North America to have substantial revenue growth in intravitreal (IVT) injectables Market

North America region shown to have high growth inintravitreal (IVT) injectables market. Low vision and blindness are prevailing in the region and high prescription of anti-VEGF intravitreal (IVT) injectables medication has increases the growth of intravitreal (IVT) injectables market. It is estimated that intravitreal (IVT) injectables create an incremental $ opportunity worth US$ 4,350 Mn between 2018 and 2028.

Get To Know Methodology of Report @ https://www.persistencemarketresearch.com/methodology/25906

Lucentis marketed by Roche and Eylea marketed by Regeneron in the United States, are the commonly prescribed biologics use in intravitreal (IVT) injectables. Apart from this, Avastin and Macugen are also widely used in intravitreal (IVT) injectables market.

The North America region holds a significant share in intravitreal (IVT) injectables among all other regions, due to the increase in prescription of retinal biologics, high healthcare facilities and availability and usage of expensive drugs.

Access Full Report @ https://www.persistencemarketresearch.com/checkout/25906

Intravitreal (IVT) Injectables Market: Segmental Analysis

The global intravitreal (IVT) injectables market has been segmented on the basis of drug class, indication and distributional channel. On the basis of drug class, the intravitreal (IVT) injectables market has been segmented into anti-VEGF, corticosteroids, antibiotics, antivirals and antifungals. Based on indication, the intravitreal (IVT) injectables market has been segmented into diabetic retinopathy, macular degeneration, endophthalmitis, retinal vein occlusions and others.

In terms of revenue, the anti-VEGF segment is expected to have a major share in intravitreal (IVT) injectables during the forecast period as it prevents angiogenesis and also minimize the leakage of fluid that occurs due to retinal diseases.

On the basis of distributional channel, the intravitreal (IVT) injectables market has been categorized into hospital pharmacies, retail pharmacies, drug stores, mail order pharmacies and others. The hospital pharmacies is expected to have high revenue growth in intravitreal (IVT) injectables, owing to the availability of biologics and increase in prescription of anti-VEGF drugs.

Report Highlights:

Explore Extensive Coverage of PMR`sLife Sciences & Transformational HealthLandscape

Opioids MarketOpioids Market Segmented By Morphine, Codeine, Fentanyl, Meperidine, Methadone Product in Analgesia, Cough Suppression, Diarrhea Suppression.For More Information

Non Infectious Macular Edema Treatment MarketNon-infectious Macular Edema Treatment Market Segmented By Anti-VEGF, Corticosteroids, Immunosuppressant, Biologics Drug with Non-infectious Uveitic Macular Edema, Diabetic Macular Edema, Retinal Vein Occlusion with Macular Edema Indication by Oral, Parenteral, Topical Route of Administration.For More Information

About us:

Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics andmarket research methodologyto help businesses achieve optimal performance.

To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.

Our client success stories feature a range of clients from Fortune 500 companies to fast-growing startups. PMRs collaborative environment is committed to building industry-specific solutions by transforming data from multiple streams into a strategic asset.

Contact us:

Ashish KoltePersistence Market ResearchAddress 305 Broadway, 7th FloorNew York City,NY 10007 United StatesU.S. Ph. +1-646-568-7751USA-Canada Toll-free +1 800-961-0353Sales[emailprotected]Websitehttps://www.persistencemarketresearch.com

See the original post here:
Intravitreal IVT Injectable Market Worth Will Reach US$ 4350 Mn According To Forecast By 2028 - Cole of Duty

Read More...

Educate Patients About the Basics of Blepharitis – Pharmacy Times

Friday, May 15th, 2020

Yvette C. Terrie, BSPharm, RPh

The common ocular condition accounts for an expanding percentage of primary care medical visits.1 Although blepharitis does not typically result in blindness, left intreated, it has can cause corneal neovascularization and ulceration, keratopathy, and permanent alterations in eyelid morphology.2 The pathophysiology is thought to stem from a bacterial infection, dermatologic conditions such as rosacea and seborrheic dermatitis, or a problem with the oil glands near the base of the eyelids.3 Common clinical presentation includes burning and/or itching of the eyelid margins and/or conjunctival irritation with lacrimation, photosensitivity, or the sensation of a foreign body.2,3

Blepharitis is classified into 2 types, according to the American Optometric Association.2 Anterior blepharitis affects the outside front of the eyelid, where the eyelashes are attached. The 2 most common causes of anterior blepharitis are bacteria (Staphylococcus) and scalp dandruff.2 Posterior blepharitis affects the inner eyelid and is caused by problems with the oil (meibomian) glands in this area. Two dermatologic disorders can cause this form of blepharitis: acne rosacea, which leads to erythema, and seborrheic dermatitis.2

Self-treatable ophthalmic disorders primarily affect the eyelids, but it is important that patients always seek medical guidance to determine if an infection is present and rule out a more complicated condition or disorder.4 Pharmacists can assess if self-treatment is appropriate, direct patients to seek further medical care when warranted, and provide information about blepharitis. They can also educate patients about eyelid hygiene, including related nonprescription products, and the numerous OTC artificial tear products that may provide symptomatic relief.

PRACTICING PROPER EYELID HYGIENE Even with successful treatment, blepharitis may recur. Treatment depends on the severity and type of blepharitis, and some cases require more complex regimens. Blepharitis rarely disappears completely.5,6 Proper eyelid hygiene is the foundation of treatment and is effective in most cases.3

For a bacterial infection that does not respond to eyelid hygiene, a prescription topical antibiotic ointment may be warranted.5 A severe case may call for an oral antibiotic and a short course of a steroid.3,5 Because most blepharitis cases are chronic, patients need to follow a good hygiene regimen to prevent recurrence. Recommended measures include:2,3,5

PATIENT EDUCATION RESOURCES American Academy of Ophthalmology: aao.org/eye-health/diseases/ what-is-blepharitisMayo Clinic: mayoclinic.org/diseases-conditions/blepharitis/symptoms- causes/syc-20370141National Eye Institute: nei.nih.gov/learn-about-eye-health/eye-conditions- and-diseases/blepharitis

REFERENCES

Continued here:
Educate Patients About the Basics of Blepharitis - Pharmacy Times

Read More...

Retinitis Pigmentosa (RP) Market Poised to Expand at a Robust Pace Over 2025 – Cole of Duty

Friday, May 15th, 2020

Retinitis pigmentosa, is a condition where patients typically loses ability to see at night in young years, side vision in middle age, and focal vision in later in his/her life due to relentless loss of cone photoreceptor cells. Proportions of retinal capacity, for example, the electroretinogram, demonstrate that photoreceptor capacity is decreased normally quite before symptomic night visual impairment, visual-field scotomas, or diminished visual sharpness emerge. Retinitis Pigmentosa (RP), an acquired retinal condition that causes retinal depletion, is an uncommon illness. Its underlying manifestations are decreased night vision along with loss of fringe vision. It slowly causes visual impairment.

Get Exclusive PDF Sample Copy Of This Report:https://www.tmrresearch.com/sample/sample?flag=B&rep_id=91

There is no conclusive remedy for retinitis pigmentosa. Hence medical institutions and various research and development centers are researching to develop a full proof cure for this disease which is boosting the growth of global retinitis pigmentosa market.

Retinitis pigmentosa, in which patients usually lose night vision in teenage years, side vision in middle age, and central vision in later life because of steady loss of cone photoreceptor cells and rod. Measures of retinal function, such as the electroretinogram, indicate that photoreceptor function is reduced usually several years before visual-field scotomas, symptomic night blindness, or reduced visual acuity arise.

As of now, there are no specific treatments available for retinitis pigmentosa. Efficient treatments for retinitis pigmentosa are much awaited, particularly for genetically defined subsets of patients. Various studies suggest that this disease affects about 1 in 4,000 individuals worldwide. Without treatment, patients permanently lose central vision by the age of 60. For past many years, there have been several treatments reported, which did not completely cure the disease but were beneficial to some extent. For instance, in the past, patients used to consume a supplement of 15,000 I.U. of Vitamin A and possibly fish oilto address this conditions. In 2011, a method of treatment was patented, in which a medical dose of insulin, IGF-1, and chlorin e6 was used. Another treatment option which was proposed in November 2012 was a combined treatment regimen ofoily fish (DHA), vitamin A palmitate, and lutein. This treatment was reported to slow vision loss in people suffering from the disease. Rare forms may also be treated with vitamin supplements or diet modification.

Looking at the immense growth potential, several new players are likely to venture into the global retinitis pigmentosa market, thereby making it a highly competitive arena in the near future.

Retinitis Pigmentosa (RP), an inherited retinal condition causing retinal degeneration and visual field loss, is a rare disease. Its initial symptoms are reduced nightvisionand loss of peripheral vision. It gradually causes blindness. There is no definitive cure for retinitis pigmentosa. Therefore, the market for treating this genetic disorder is vastly untapped. The available therapies apply various approaches such as stem cell therapy and transcorneal electric stimulation therapy. However, such therapies have not been approved of unanimously on account of certain intrinsic limitations.

A range of services and devices are available to aid people with vision loss to conduct their day to day activities independently. Those include anything from a vision aid and an eye care professional to orientation and mobility specialists and certified low vision therapists, among others.

The global retinitis pigmentosa market has been treading a healthy growth path due to limited availability of therapeutics to cure this rare disease which has opened up a window of opportunity for new therapies and treatments. In fact, most people afflicted with the genetic disorder progress to the advanced stage of retinitis pigmentosa because of the dearth of proper cure. This has generated demand for retinal prosthesis devices for restoring the lost vision. Second Sight Medical Products, Inc., for example, offers FDA approved Argus II retinal prosthesis system meant for patients with advanced retinitis pigmentosa. This device does the function of degenerated retinal cells and enhances the patients ability to see images and movement.

A new approach known as optogenetics, which involves applying gene therapy for restoring vision, is currently being researched upon by companies operating in the ophthalmology market. It helps to power cells, especially ganglion cells, to respond to light after the degeneration of rod cells and cone cells. Further, the orphan drug designation given by the FDA and European Commission to ReN003 by ReNeuron in the U.S. and Europe in 2013 is another positive development in the market. ReN003 is a retinalstem cell therapycandidate.

Buy This Report @https://www.tmrresearch.com/checkout?rep_id=91<ype=S

Based on geography, the global retinitis pigmentosa market can be segmented into North America, Europe, Asia Pacific, and the Rest of the World. Among them, North America and Europe dominate the market powered by the developed markets of the U.S and U.K. where exhaustive research and development activities have been carried out in this direction. However, the Asia Pacific retinitis pigmentosa market is also poised for growth due to the large patient pool in the region, who need to be treated for retinitis pigmentosa. The Rest of the World also has a substantial number of people suffering from this rare genetic disorder.

Companies Mentioned in Report

To present an study the current competitive dynamics in the global retinitis pigmentosa market, the report has profiled some of the major players involved in the development and commercialization of products in the field such as ReNeuron Group plc, Amarantus BioScience Holdings, Inc., Ocugen, Inc., ReGenX Biosciences, LLC, Sucampo Pharmaceuticals, Orphagen Pharmaceuticals, Inc., Inc., and Okuvision GmbH.

To know more about the table of contents, you can click @https://www.tmrresearch.com/sample/sample?flag=T&rep_id=91

About TMR Research

TMR Research is a premier provider of customized market research and consulting services to busi-ness entities keen on succeeding in todays supercharged economic climate. Armed with an experi-enced, dedicated, and dynamic team of analysts, we are redefining the way our clients conduct business by providing them with authoritative and trusted research studies in tune with the latest methodologies and market trends.

Continue reading here:
Retinitis Pigmentosa (RP) Market Poised to Expand at a Robust Pace Over 2025 - Cole of Duty

Read More...

The centre’s wilful blindness and control freakery hinders the Covid response – Local Government Chronicle

Friday, May 15th, 2020

Councils face an uphill struggle when their budget shortfalls are not covered and local expertise is not trusted by ministers, writes LGC editor Nick Golding.

There has been criticism lately in certain quarters of journalists and commentators for their raising of deficiencies in the national coronavirus response. Questioning and scrutiny are seen as tantamount to treachery, working against the war effort and undermining ministers who face the unenviable task of having to take unprecedented action with imperfect information. Of course, this criticism is misplaced. It is the most fundamental job of the journalist to expose inefficiency, hypocrisy, mistruths and failure and far from being a fair-weather luxury this role becomes even more important during a crisis when such failings have an immediate detrimental effect on wellbeing and even survival.

LGC has been asking searching questions of the government, mainly around two key themes. First, do councils have the funding to protect their communities and, second, is local expertise being used to its full potential and sufficiently supported in an increasingly centralised operation? The answer to both questions from our readership has been an overwhelming no.

Councils have been regularly undermined by the centre

On finance, the mood music was initially positive. When ministers were telling councils to do whatever is necessary to support their place, the implication was their work would be fully funded. It seems communities secretary Robert Jenrick has lost a financial battle with the Treasury and his promise has been diluted to covering the costs of specific tasks councils have been told to do. Any expenditure on top of this will be merely taken into consideration while councils projections of sector-wide multi-billion pound income losses are deemed highly speculative. And it would, we were told, create a moral hazard to bail out authorities that had made unwise commercial investments, upon the success of which they are reliant. Mr Jenrick made no mention of the fact councils have done this the vast majority of them acting responsibly to try to recoup the funding they have lost at the hands of Conservative ministers.

To ignore councils dire straits amounts to delusional, head-in-sand, ostrich leadership. While the exact size of each councils shortfall for the rest of 2020-21 is uncertain, one thing is clear: unless far more funding than the current 3.2bn arrives, councils will collapse and local services will be decimated. Does Mr Jenrick really want that? Councils are having to take decisions now about expenditure for the rest of the year and need a clear commitment that their budget shortfalls will be covered. Mr Jenrick diluted his promises, condemning local service users to misery just as Boris Johnson was pledging no return to austerity, a meaningless statement unless backed by resources.

On the second theme, councils have been regularly undermined by the centre (despite the belated move which went live today for directors of public health to lead on care home testing). Councils have been bypassed on contact tracing, coordination of volunteers and sharing of data for the shielding service. The social care workforce has often been near the back of the queue for personal protective equipment while deaths in care homes were not even included in NHS England daily statistics for most of the crisis to date. And why have we not seen James Jamieson or Mark Lloyd, respectively the chair and chief executive of the Local Government Association, behind a lectern at the Downing Street briefing? They havent been invited because councils are not seen as a sufficiently important partner by the centre.

All of this undermines the effort to reduce the spread and impact of coronavirus. While aspects of the central response have been impressive, government incompetence, wilful blindness and control freakery are hindering councils efforts. Perhaps the greatest challenge now is rebuilding shattered local economies an operation that can only be successful if undertaken by empowered, properly funded local leaders. Every central action needs to be scrutinised, questioned and debated to ensure it aids the local response to coronavirus because at present too many are thwarting it. As Britains Covid-19 death rate soars higher than the rest of Europe there is a moral imperative to ask why? and can we as a nation do better?.

Original post:
The centre's wilful blindness and control freakery hinders the Covid response - Local Government Chronicle

Read More...

The Cell Therapy Industry to 2028: Global Market & Technology Analysis, Company Profiles of 309 Players (170 Involved in Stem Cells) -…

Friday, May 15th, 2020

DUBLIN--(BUSINESS WIRE)--The "Cell Therapy - Technologies, Markets and Companies" report from Jain PharmaBiotech has been added to ResearchAndMarkets.com's offering.

The cell-based markets was analyzed for 2018, and projected to 2028. The markets are analyzed according to therapeutic categories, technologies and geographical areas. The largest expansion will be in diseases of the central nervous system, cancer and cardiovascular disorders. Skin and soft tissue repair as well as diabetes mellitus will be other major markets.

The number of companies involved in cell therapy has increased remarkably during the past few years. More than 500 companies have been identified to be involved in cell therapy and 309 of these are profiled in part II of the report along with tabulation of 302 alliances. Of these companies, 170 are involved in stem cells.

Profiles of 72 academic institutions in the US involved in cell therapy are also included in part II along with their commercial collaborations. The text is supplemented with 67 Tables and 25 Figures. The bibliography contains 1,200 selected references, which are cited in the text.

This report contains information on the following:

The report describes and evaluates cell therapy technologies and methods, which have already started to play an important role in the practice of medicine. Hematopoietic stem cell transplantation is replacing the old fashioned bone marrow transplants. Role of cells in drug discovery is also described. Cell therapy is bound to become a part of medical practice.

Stem cells are discussed in detail in one chapter. Some light is thrown on the current controversy of embryonic sources of stem cells and comparison with adult sources. Other sources of stem cells such as the placenta, cord blood and fat removed by liposuction are also discussed. Stem cells can also be genetically modified prior to transplantation.

Cell therapy technologies overlap with those of gene therapy, cancer vaccines, drug delivery, tissue engineering and regenerative medicine. Pharmaceutical applications of stem cells including those in drug discovery are also described. Various types of cells used, methods of preparation and culture, encapsulation and genetic engineering of cells are discussed. Sources of cells, both human and animal (xenotransplantation) are discussed. Methods of delivery of cell therapy range from injections to surgical implantation using special devices.

Cell therapy has applications in a large number of disorders. The most important are diseases of the nervous system and cancer which are the topics for separate chapters. Other applications include cardiac disorders (myocardial infarction and heart failure), diabetes mellitus, diseases of bones and joints, genetic disorders, and wounds of the skin and soft tissues.

Regulatory and ethical issues involving cell therapy are important and are discussed. Current political debate on the use of stem cells from embryonic sources (hESCs) is also presented. Safety is an essential consideration of any new therapy and regulations for cell therapy are those for biological preparations.

Key Topics Covered

Part I: Technologies, Ethics & Regulations

Executive Summary

1. Introduction to Cell Therapy

2. Cell Therapy Technologies

3. Stem Cells

4. Clinical Applications of Cell Therapy

5. Cell Therapy for Cardiovascular Disorders

6. Cell Therapy for Cancer

7. Cell Therapy for Neurological Disorders

8. Ethical, Legal and Political Aspects of Cell therapy

9. Safety and Regulatory Aspects of Cell Therapy

Part II: Markets, Companies & Academic Institutions

10. Markets and Future Prospects for Cell Therapy

11. Companies Involved in Cell Therapy

12. Academic Institutions

13. References

For more information about this report visit https://www.researchandmarkets.com/r/7h12ne

Follow this link:
The Cell Therapy Industry to 2028: Global Market & Technology Analysis, Company Profiles of 309 Players (170 Involved in Stem Cells) -...

Read More...

Medical School: Who gets in and why – Stuff.co.nz

Friday, May 15th, 2020

Few would question the benefits of a medical profession which reflects the socio-demographic make-up of New Zealand. Our medical schools are now boosting Mori, Pasifika and rural student numbers but have they got the balance right? MARTIN VAN BEYNEN reports.

Harry* is a bright and social 18-year-old who was always passionate about becoming a doctor. He was brought up in a well-off home by professional parents but family issues meant life was no bed of roses.

He completed the first year health science course at the University of Otago last year with an A+ average grade and also managed a top score in the required University Clinical Aptitude Test (UCAT). He was absolutely gutted and so were his parents when he was not accepted into Otago Medical School.

Incredibly, his academic results were not good enough. His disappointment was not helped by students with far lower grades and poorer UCAT results being accepted under special categories including Mori and Pasifika, rural and low socioeconomic.

Harry, of European descent, was not alone in his disappointment. Other European and Asian students faced similar setbacks. At least one family has threatened legal action.

READ MORE:* She aspired to be a doctor at 10, to 'make a point' that Mori can * We need more diversity in our health system - entrance schemes help* Emails reveal Otago and Auckland's med school meddling * Auckland and Otago medical schools undermine Waikato bid* Record numbers of Maori doctors graduate from med school

Its a touchy subject. Few would disagree that elite professions like medicine should reflect the socio-demographic make-up of the general population. Evidence suggests that doctors who have more things in common with their patients will be more empathetic and have more success in diagnosis and getting patients to follow recommended treatments.

But have the medical schools gone too far in trying to redress the balance by squeezing out a growing number of general students? And have entry requirements become too easy to manipulate?

For a long time the medical school intake from some sections of society, notably Mori and Pasifika, was much lower than their proportion of the population.

Only a decade ago, a mere 7.6 per cent of new domestic medical students at Otago identified as Mori and 2.7 per cent as Pasifika. The ramifications show up in the current medical workforce in which only 3.4 per cent are Mori and 1.8 per cent Pasifika. Their respective proportions of the total population are about 15 per cent and 8 per cent.

However, a big change was seen after more robust affirmative action policies were implemented at medical schools after 2010. By 2016 Mori and Pasifika students entering Otago Medical School had increased by 179 per cent Mori were about 16 per cent of domestic students and Pasifika students counted for 5.6 per cent.

One group, however, showed little improvement. In 2010 only 2.4 per cent of Otago medical students had attended a secondary school with a socioeconomic decile of less than four.

By 2016, the percentage had grown to 4.7 per cent.

Wiremu*, now training to be a general practitioner, was one of those students who benefited from affirmative policies designed to increase Mori in the medical workforce. A product of kohanga reo and a low decile Mori immersion primary school, he had a flair for science and wanted to work with people.

His low decile high school had not prepared him well for the highly competitive intermediate year at Auckland University, but he worked his guts out and was accepted into its medical school.

His life experience in different sections of the community, including gang families, enables him to relate to patients better than a book-smart, nerdy type from a privileged background, he says.

As a junior doctor, he was often able to get through to certain Mori patients just by saying his name.

Supplied

Some people cant see the difference between equity and equality," says a junior doctor.

They suddenly realised there was a Mori person on the other side. You just have to see their face when I say Kia Ora Im Wiremu some of them go, True Bro I thought you were Pkeh. In certain circumstances we will have a chat in Mori and obviously that's useful. Then we have a brief introduction period, you get to know the other person. Pronouncing someones name correctly is massive.

He says getting more Mori into medical schools wont fix the inequities in health outcomes but it will help.

Some people cant see the difference between equity and equality. Ive learned so much about why Mori are the way we are today. Sometimes you have to direct more resources to some people for outcomes to be equal.

Some students manipulate the system, but they are a small minority, he says.

For this years intake, Otago had 202 places available for first year students entering from its intermediate year. (Otago does not take first year students from other universities).

Of those, 120 were given to those entering under a raft of categories.

Of those, 58 were Mori, 20 were Pasifika, 1 Mori/Pasifikaand 29 entered through the rural gate. Eleven students went in under the low socio-economic category and one under a new refugee category. That left only 82 general entry places (40 per cent).

As well as the 202 places for first year students, Otago medical school fills another 80 places with graduates. Overall for 2020, Mori and Pasifika make up 32 per cent of students starting at the school, while 14 per cent have rural backgrounds, 4 per centlow socioeconomic, and 1per cent refugee.

Auckland medical school shows a similar pattern. For the 2020 year it had 185 places for first year health science or bio-medicine students. Mori and Pasifika took up 52 places, rural got25, disabled 2, low socioeconomic 5 and refugee1. That left 101 places (55 per cent) for general entry students.

Looking at percentages for the 2020 intake, Mori and Pasifika students took up nearly 40 per cent of the places at Otago for first year health science students and 28.1 per cent of the total places for first year students at Auckland.

At Otago that meant general entry students had to get, as one student put it, ludicrously high grades to be accepted. In fact candidates needed at least a 94 per cent average mark for their seven papers to get an offer.

The father of a European student who missed out on this years intake at Otago despite stellar marks says he can understand why district health boards and central government want the medical workforce to be representative.

Where I have difficultyis reconciling that with students who would make wonderful doctors and have extremely high marks being lost to the medical profession.

The average mark for the sub-category entrants is not held by the university and it was not able to provide it before deadline.

However, sub-category entrants must get a 70 per cent minimum for each paper. Those who achieve an average of at least 70 per cent can be admitted with individual subject marks under 70 per cent so long as the admissions committee is satisfied about their academic ability to complete the programme.

At Otago, a candidates overall UCAT score does not count in the assessment by the admissions committee but general candidates must score in the top 80 per cent of results for verbal reasoning and in the top 90 per cent for situational judgement.

Suppled

This could hurt:Medicine does not need society's brightest students, says a top medical educator.

Critics say the low thresholds are farcical because no-one with good enough grades to be a doctor will go below the thresholds. The university says it uses the scores when choosing between candidates who are otherwise very similar.

The thresholds do not apply to Mori and Pasifika candidates. They are assessed by reference to specific material provided by applicants about their engagement with their communities.

In Auckland, admission is based on an interview (25 per cent), first year marks (60 per cent), and the UCAT result (15 per cent).

Otago University cannot say how many Mori and Pasifika students would have met the grades required by successful general applicants in this years intake, but Professor Paul Brunton, Pro-Vice-Chancellor, Health Sciences says if affirmative action had not been undertaken both Mori and Pasifika students would have been significantly under-represented in this years class compared with the make-up of New Zealand society.

Does the medical school have a cap on sub-category students?

Brunton says the Education Act states affirmative action places can only be offered where a relevant category of applicant would otherwise be under-represented in the medical programme.

To date, the number of sub-category students we have been able to admit continues to be well below the needs of the health workforce.

The Government funds 55 rural places at each of the universities of Otago and Auckland, he says.

Medical school applicants at Otago need to meet a number of requirements to be successful under the various subcategories.

The Mori and Pasifika category requires students to verify their ancestry by, for instance, an iwi registration document or, for Pasifika, a community leaders endorsement.

Applicants under the rural category can hail from places such as Helensville and Pukekohe near Auckland, Lincoln and Rangiora on the outskirts of Christchurch and Featherston, Greytown and Martinborough near Wellington. They also include Queenstown Bay, Frankton, Cromwell and Wnaka.

Under the low socioeconomic category, candidates must have attended a decile one to three secondary school during Years 11, 12 and 13. Parental income is not considered.

JOHN KIRK-ANDERSON/STUFF

Some of Jordan Tewhaiti-Smith's relatives - including his dad - are Mongrel Mob members. They were also his biggest supporters while he studied to become a doctor. (Video first published in December 2019)

In order to apply under the refugee sub-category, candidates for admission must have either been granted refugee status in New Zealand, or have parents/primary guardian(s) who have been granted refugee status.

Affirmative action is always controversial. Critics say it breeds resentment, stigmatises those students who avail themselves of the special categories and lowers the standards and prestige of an institution.

One of the objections is that it can give an unfair advantage to privileged students who actually have little in common with the minorities with whom they claim to have some genetic link. In other words, a Mori student from a relatively privileged home could be admitted over a European or Filipino student from a poorer home despite their better marks.

During his first presidential campaign, Barack Obama, said his two daughters who have had a pretty good deal should not benefit from affirmative action, particularly when they were competing with poor white students.

Some claim the system is open to abuseby wealthy students with a distant relative who is Mori orPasifika..

"These kids are attending private schools and are being allowed into medical school without achieving like the others must. It is not achieving the aims of helping Mori, says one parent.

Another parent asked if patients were better served by doctors who were"empathetic and more academic" regardless of ethnicity.

Professor Peter Crampton, whose parents immigrated from England to New Zealand when he was 12, and who worked as a GP in Porirua, near Wellington, is one of the main architects of the Mirror on Society policy at Otago University.

A former dean of the Otago Medical School and now professor of public health in Khatu Centre for Hauora Mori, he doesnt regard the issues around special entry into medical school as highly sensitive.

He says the purpose of the university is to produce a health workforce that meets the needs of society.

The-Southland-Times

Peter Crampton, aprofessor of public health, says medical schoolsselect students "for things we can't teach".

Doctors who belong to a rural or ethnic minority are more likely to serve those communities and provide the care that is not like the care provided by others.

He draws parallels to the dearth of female doctors in the medical workforce in previous decades.

It was thought men do that job very well and although we think of that as quaint and old fashioned, its not that long ago.

Mori doctors treating Mori patients could lead to better outcomes for multiple reasons, both interpersonal and because of the way systems are set up, he says.

He agrees no guarantee exists that students admitted under the sub-categories will go on to work in those areas and says its too early to tell whether the special entry scheme is helping to improve outcomes for Mori and Pacific patients.

We dont put on any of our students, any of them, any sort of moral weight to do a particular thing.

No affirmative system will have perfect rules and perfect compliance, he says. Defining a student's rural credentialssounded simple but coming up with a transparent and fair system was tricky.

He doesnt acceptthat students being admitted under the Mori or Pasifika sub-categories, who look European and have suffered none of the deprivations of low socioeconomic Mori or Pasifika, should not be allowed to take advantage of the easier route into medical school.

Nor does he agree that if Mori or Pasifika patients are to benefit from an affinity with the doctor, the doctor should look a bit like them.

If you are saying it would help if you look Mori I reject your framing entirely. Would it help if you looked gay?

We want the health workforce to broadly reflect the communities being served so that when you come into contact with the health force, whatever that touch point might be, there is some chance that system has been influenced by health professionals who share your world view, your ethnic affiliation or your gender and you meet a health professional who you might identify with and makes you feel at home within that system.

He finds the allegation that European-lookingstudents from well-off homes with slight Mori or Pacific ancestry are rorting the system hard to get a handle on.

You're conjuring up a phenomenon that encapsulates a world view that I would like to deconstruct.

He says Mori and Pacific students have a different socio-economic profile to general entry students although it is true the research in 2016 showed little movement in admitting more students from lower decile schools.

Any system of exclusion or inclusion is going to run into its difficulties at the margins with definitions.Its not perfect or watertight. Does that discredit the system,do we throw out a system because some people might not be eligible? The health workforce needs more Mori-Pacific students. We have not specified if they be rich or poor.

Although Mori and Pasifika students coming through the intermediate year pathway into Otago medical school were exceeding their proportion of the general population, the proportion of those groups in the medical workforce realistically will not catch up not in our lifetimes.

The marks required by general entry students was very high but people needed to remember why are we are doing this.

The high marks phenomenon is an artefact of selection processes. If I ask people, what do you like to see in your doctor? they say good communicator, honesty, compassion, altruism, along those lines. They never say we want them to have had straight As at school and through university.

We can't easily measure what we need to measure. Medicine does not need society's brightest students, it benefits from them but doesn't need them. That is an artefact of career aspirations occurring over decades.

We select people to meet certain characteristics we select them for things we can't teach. It is a demanding and difficult course and it needs people who are bright, capable and highly motivated. That is not the same as saying we need the top academic students. We don't have to have them.

Medical schools were sick of using marks.

He believed the UCAT thresholds were meaningful and helped exclude candidates who could be brilliant lab scientists but no good at face-to-face medicine.

So what would he say to Harry with his tremendous marks and who had his heart set on medicine?

Iunderstand their bitter disappointment and in my counselling I strongly encourage them to explore other options. So many young people base their sense of their identity and ambition on a particular academic pathway and feel quite devastated when that is not achieved. The world is full of amazing career opportunities for the academically capable."

Does he understand their resentment?

Thats where I come back to the policy and its intention. The policies are clear. To me personally and many colleagues in the university it's completely unacceptable that we have a health workforce devoid of Mori. We are rectifying that situation. The problem is that high marks have become the passport and because I've got high marks I should be a doctor.

*Notreal names.

Link:
Medical School: Who gets in and why - Stuff.co.nz

Read More...

Page 32«..1020..31323334..4050..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick